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ABSTRACT 
 Porcine reproductive and respiratory syndrome virus (PRRSV) emerged 
worldwide approximately 25 years ago, and continues to be the most costly disease of 
modern swine production. The genetic diversity of PRRSV is one of the major hurdles 
encountered in attempts to reduce the effects of the virus through vaccines that provide 
broad cross-protection. The objective of this research is to examine the efficacy of a 
recently approved vaccine, Fostera™ PRRS, in growing pigs against separate challenges 
with heterologous PRRSV strains belonging to lineage 9 and lineage 1. The selected 
challenge viruses were isolated from recent PRRSV field infections in swine that 
originated in Iowa. The results of both studies indicate vaccine-induced immunity confers 
partial protection against the effects of heterologous PRRSV infection, as measured by 
reduced quantities of virus in serum, oral fluids and bronchoalveolar lavage fluid, and an 
increase in average daily gain in vaccinated pigs compared to non-vaccinated pigs 
challenged with the same virus. The two studies resulted in differing levels of protection 
as measured by severity of lung lesions and quantities of virus in tissues; these 
differences may be due to several factors, including variations in study design or in the 
degree of heterogeneity of the challenge viruses. The results show that Fostera™ PRRS 
vaccine can provide growing pigs with partial protection against heterologous challenge 
with currently circulating PRRSV. To improve prevention and control efforts, further 
investigations are needed into the cross-protection elicited by commercial PRRSV 
vaccines against contemporary, heterologous virus strains. 
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CHAPTER 1: INTRODUCTION 
Background 
Porcine reproductive and respiratory syndrome virus (PRRSV) is the most costly 
pathogen currently affecting the swine industry. Vaccines are commonly used in various 
programs designed to mitigate the impact of disease in growing pigs. Due to the genetic 
diversity of PRRSV, vaccines do not result in complete protection against challenge with 
heterologous viruses. The effectiveness of PRRSV vaccines can be evaluated by several 
methods, including increased average daily gain, decreased lung lesions, and decreased 
viral replication within the animal. In order to make significant progress towards 
decreasing the impact of PRRSV infection in swine, approved vaccines should elicit 
significant cross-protective immunity that prevents infection with and transmission of 
PRRSV strains representative of those present in current production settings. 
 
Objective 
The objective of this research was to determine the efficacy of a recently 
approved commercial modified live PRRSV vaccine, Fostera™ PRRS, against challenge 
with two field strains of considerable genetic diversity compared to the strain represented 
in the vaccine and belonging to different PRRSV lineages. 
 
Thesis Organization 
 This thesis consists of an introduction, literature review, two original research 
chapters that will be submitted for publication, and a conclusion. Chapter 2 serves as a 
literature review of several topics regarding PRRSV that are pertinent to the study design 
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of research trials presented in later chapters. Topics include PRRSV emergence, 
importance to the industry, viral structure and pathogenesis, immune response, control 
strategies, vaccination, and a summary of published PRRSV challenge studies. 
 Chapters 3 and 4 present original research regarding the efficacy of a commercial 
PRRSV vaccine, Fostera™ PRRS. The author’s role in each study included development 
of study design, the growth, selection and titration of viral isolates, execution of the 
animal studies, sample collection and necropsy of experimental animals and 
interpretation of results. Chapters are presented as prepared for publication. Chapter 5 
consists of a short discussion of results and conclusions. 
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CHAPTER 2: LITERATURE REVIEW 
 
Introduction 
 In the late 1980’s and early 1990’s outbreaks of infertility and respiratory disease 
of unknown origin were described in the swine populations of North America, Europe, 
and Asia. After being referred to by several different names (such as swine infertility and 
respiratory syndrome, porcine epidemic abortion and respiratory syndrome, and mystery 
swine disease), a consensus was reached that the clinical description would be known as 
porcine reproductive and respiratory syndrome (PRRS). A virus associated with the 
disease was first isolated in Europe in 1991 and designated as the Lelystad virus,
1
 with a 
North American strain isolated shortly thereafter; collectively, the new pathogen became 
known as porcine reproductive and respiratory syndrome virus (PRRSV). A retrospective 
study found anti-PRRSV antibody positive serum in Canada as early as 1979.
2
 This is the 
earliest seropositive report of PRRSV, suggesting the virus was present in the swine 
population for several years before reports of clinical disease; however, PRRSV was not 
detected in the seropositive samples. 
As the name suggests, the clinical disease caused by PRRSV includes both 
reproductive and respiratory manifestations. The reproductive component of the disease 
is characterized by increased abortions in sows and decreased fertility in both sows and 
boars; the respiratory component of PRRSV infection is characterized by interstitial 
pneumonia and dyspnea in pigs of any age.
3,4
 The severity of clinical signs apparent 
during PRRSV infection is often dependent upon immune status of the animal, the strain 
of the virus,
5,6
 and the presence of viral co-infections (such as swine influenza) or 
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secondary bacterial infections (such as Haemophilus parasuis, Pasteurella multocida, 
and Streptococcus suis).
4
 Despite the vast amount of research into the dynamics of 
PRRSV infection, other unidentified factors may play a role in disease severity. 
 A study in 2005 estimated that clinical disease attributable to PRRSV infection 
costs the United States (US) swine industry approximately $560 million annually due to 
increased mortality, decreased reproductive performance, and reduced feed efficiency; 
88% of these costs were attributed to effects of the virus in growing pigs.
7
 Using year 
2000 survey results from the National Animal Health Monitoring System (NAHMS), the 
researchers found that nearly 45% of breeding females were in PRRSV-positive herds. 
The study did not take into account the cost of vaccination, biosecurity measures, 
monitoring of endemic herds, or the effect of subclinical disease. A more recent study in 
2012 estimated the cost of lost productivity due to PRRSV at $664 million, with growing 
pigs accounting for 55% of the total economic loss.
8
 The researchers used a survey of 
swine veterinarians to gather data on incidence of PRRSV as well as additional 
production costs that were not evaluated in the previous study. Based on the survey 
results, they estimated an additional cost of $477 million to US swine producers in 
animal health, biosecurity, and outbreak related expenses attributed to PRRSV.  
 
PRRS Virus and Pathogenesis 
Porcine reproductive and respiratory syndrome virus is a positive sense, single-
stranded RNA virus belonging to the order Nidovirales, the family Arteriviridae, and the 
genus Arterivirus,
9
 which also includes equine arteritis virus, lactate dehydrogenase 
elevating virus of mice, and simian hemorrhagic fever virus.
10
 The PRRSV genome is 
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approximately 15 kb, and nine open reading frames (ORF) have been identified.
11
 ORF1a 
and ORF1b make up a large portion of the genome and encode for various non-structural 
proteins (NSP) involved with viral replication and subgenomic transcription, including 
RNA-dependent RNA polymerase, while ORFs 2a, 2b, 3 and 4 encode for minor 
structural proteins found in the viral envelope.
11
 Minor structural proteins may play a role 
in determining viral tropism through interaction with target cell receptors. 
The major structural and envelope proteins of PRRSV are encoded by ORFs 5 
through 7.
12
 The first major envelope protein, GP5, is encoded by ORF5 and is the most 
highly variable protein of PRRSV.
13
 Variability in GP5 may contribute to the lack of 
immune cross protection between virus isolates,
14
 and the results of several studies 
suggest that antibodies against GP5 were the most effective at virus neutralization.
15,16,17
 
A second major envelope protein, the M protein, is encoded by ORF6
10
 and is highly 
conserved across PRRSV strains.
18
 Research suggests that GP5 and M protein may be 
involved in viral attachment to and internalization by macrophages,
19,20,21
 and research 
has shown both proteins are vital components of the envelope; deletion of either ORF5 or 
ORF6 results in a failure of viral reproduction.
22
 The nucleocapsid (N) protein is encoded 
by ORF7.
11
 The N protein is the most immunogenic protein of PRRSV, with anti-N 
protein antibodies appearing as soon as 5 days after infection; however, these antibodies 
do not play a role in virus neutralization.
17,23
  
Within the host PRRSV displays a predilection for monocyte derived cells, 
particularly those in the lung and lymphoid tissues. The virus displays a particular 
tropism for pulmonary alveolar macrophages,
24
 both in vitro and in vivo. In addition, 
several cell lines derived from monkey kidney cells have been used to grow and study 
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PRRSV.
25,26
 A cell surface molecule, heparan sulfate, has been shown to interact with the 
M/GP5 proteins on the PRRSV envelope.
19
 This molecule is found on many cells and 
although not necessary for viral infection, it is thought to loosely adhere to and 
concentrate the virus on the cell suface.
27
 The macrophage-restricted protein sialoadhesin 
has been shown to be necessary for virus attachment and internalization, through the 
binding of the M/GP5 proteins.
28,29,30
 Release of the virus within the cell and viral 
uncoating has been shown to involve a transmembrane protein, CD163.
31,32
  Once inside 
susceptible macrophages, several proteases are also involved in uncoating the virus.
33
 
Infection with PRRSV does not only affect macrophages, but can also induce apoptosis 
of nearby uninfected cells.
34
  Infection also impairs macrophage function, which reduces 
basic immune physiologic mechanisms such as phagocytosis,
35,36
 and can also induce 
apoptosis of infected cells.
37
  
Direct contact with infected tissues or fluids from swine and aerosolization of the 
virus are the most common routes of PRRSV transmission. After initial infection and 
replication, viral particles are released from the cell and can readily spread throughout the 
body via the bloodstream. Viral replication markedly increases the amount of infectious 
virus, and replication persists in macrophages of the lung, tonsil, and lymphoid 
organs.
38,39
 Although viremia is typically resolved after 28 days, viral RNA has been 
detected in serum up to 251 days post infection,
24,40
 and in congenitally infected pigs for 
up to 228 days.
41
 Persistence may be due to immune modulation through altered cytokine 
expression,
42
 ineffective cell-mediated immune response,
23
 shielding of virus and viral 
proteins within endosomes,
43
 and/or antibody-mediated enhancement.
44
 Once infection is 
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established the virus is shed in most bodily fluids/secretions: virus has been isolated from 
serum, semen, saliva, feces, urine, and nasal secretions.
4
 
Clinical signs in PRRSV-infected growing pigs include fever, anorexia, dyspnea, 
and lethargy, and are usually more severe in younger pigs.
4
 Gross lesions typically 
include a mottled-tan, non-collapsing lung with markedly enlarged lymph nodes 
throughout the body.
5,45
 Microscopic lung lesions include lymphocytic and macrophagic 
interstitial pneumonia commonly accompanied by type 2 pneumocyte hypertrophy, 
necrotic macrophages, and cellular debris accumulations within alveoli.
46
 Infection in 
pregnant sows is characterized by an increase in abortions, stillbirths, mummified fetuses, 
and infertility.
47
 Pathologic lesions reported in sows or piglets from outbreaks of 
reproductive failure are inconsistent, non-specific, and/or absent. Clinical signs, gross and 
microscopic lesions can vary due to differences in the virulence of the PRRSV strains.
5,6
  
  
Viral Classification and Diversity 
 European PRRSV strains are also known as type 1 PRRSV, with the Lelystad 
virus as the prototype strain. North American strains are known as type 2 PRRSV, with 
the prototype strain VR-2332. Despite disease emergence at nearly the same time, there is 
considerable genetic diversity both between and within the two genotypes. Genetic 
sequence homology between type 1 and type 2 PRRSV in various regions of the genome 
is 55-79%.
13,48,49,50
 While diversity between the two types varies, it is common for strains 
within each genotype to demonstrate only 80-85% homology at ORF5. There are also 
significant differences in antigenicity between genotypes.
51
 The large disparity in genetic 
and antigenic viral characteristics between genotypes suggests that the original virus 
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species underwent an initial divergence event, with each genotype acquiring considerable 
genetic diversity while being isolated to their respective continents and swine 
populations.
52
  
 Due to the genetic, antigenic, and pathogenic variability within genotypes several 
other classification methods have been developed in an attempt to more closely group 
similar PRRSV strains. One early method of virus classification, that was initially 
developed to differentiate vaccine strains from field strains, involves analysis of the 
restriction fragment length polymorphism (RFLP) of each virus strain.
53
 Determination of 
the RFLP patterns involves enzymatic digestion of an amplified ORF5 fragment by a set 
of three restriction enzymes. Digestion with each enzyme can result in several possible 
patterns; the cut pattern for each enzyme is given a number, and a three-number RFLP 
code is assigned to the virus (for example, RFLP 1-7-4).  
While this method is fairly convenient, it does not represent an accurate 
comparison of viral genotypes. The RFLP code is essentially a description of the ORF5 
sequence, which is highly variable and has little predictive value regarding the 
phenotype, antigenicity, or pathogenicity of the virus. Furthermore, enzymatic digestion 
of ORF5 relies on specific genome sequences, which can change as the virus mutates 
during replication within pigs.
54
 Using PRRSV strain VR-2332, researchers performed 13 
serial passages of virus in pigs and analyzed the RFLP patterns of the resulting isolates.
55 
Twenty percent of the recovered viruses had a different RFLP code than the initial 
challenge virus, despite a change to the ORF5 sequence of only 0.5-1.45%. The findings 
suggest that closely related viruses based on sequencing may have different RFLP codes. 
While the different enzymatic digestion patterns were initially few in number, an increase 
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in testing along with ongoing genetic mutation has led to an increase in the number of 
digestion patterns and the number of distinct RFLP codes.
52
  
 In response to the increasing number of available ORF5 genomic sequences and 
in an attempt to group similar viruses more accurately, a system was developed that 
classifies type 2 PRRSV strains based on their ORF5 sequence.
56
 Researchers used over 
8,000 ORF5 sequences available from GenBank to create nine distinct phylogenetic 
PRRSV lineages. This classification scheme resulted in groups of virus strains that were 
less than 11% diverse within lineages. Lineages 3 and 4 represent a small number of 
PRRSV sequences, all of which were found in Asia. Lineages 2, 6 and 7 are also 
relatively small and mainly contain virus isolates from the US.  
 The vast majority (>85%) of PRRSV isolates cluster in one of the four remaining 
lineages, each containing virus strains from around the world. Lineage 5 has relatively 
low intralineage diversity, and contains the historical isolate VR-2332 (the type 2 
prototype strain). Lineage 8 contains the historical isolates SDSU-73 and JA-142. 
Lineages 1 and 9 contain the largest number of isolates, and also the highest intralineage 
diversity of the four large lineages. Lineage 1 contains the historical isolate MN-184.
56
  
 There are several mechanisms that may explain the vast amount of genetic 
diversity present in PRRSV. The primary culprit is thought to be error prone RNA 
polymerase and the lack of a corrective mechanism to ensure genomic integrity during 
replication. The rate of nucleotide substitution in PRRSV is the highest of all RNA 
viruses.
57
 Genetic recombination has been shown to occur, and may play a significant 
role in viral diversity.
58,59
 Host induced mutation using cytidine deaminase enzymes has 
also been considered a mechanism capable of driving genetic diversity in RNA viruses.
60
  
10 
 
  
Immune Response to Infection 
 While infection with PRRSV eventually induces protective immunity against the 
challenge strain, development of immune protection is slow and cross-protection between 
genetically diverse strains is generally incomplete and highly variable. Evidence suggests 
this may be due to a weak innate immune response by the target cell of PRRSV, the 
pulmonary alveolar macrophage. Viruses typically elicit the production of interferon after 
infection of a host cell, which increases the production of cytokines that work collectively 
to suppress viral protein synthesis and replication.
61
 Significantly increased cytokine 
production, such as interferon-alpha and tumor necrosis factor-alpha, is a not a feature of 
early PRRSV infection,
42,62,63
 and different field isolates have been found to have 
differing abilities to induce cytokine production.
64
 Low amounts of interferon production 
may also lead to a lack of natural killer cell activation.
65
 Decreased to absent cytokine 
production early in infection may play a part in the delayed humoral immune response as 
well as the prolonged course of infection. Several studies have shown an eventual 
elevation in various cytokine levels (interferon-gamma, tumor necrosis factor, and 
interleukin-10) within the lung or BALF collected from infected pigs, but the increase 
was not apparent until 7-10 days after infection.
66,67,68
 
The humoral immune response to PRRSV can be detected within one week of 
infection. IgM antibodies to PRRSV are generated within 5-7 days of infection, with peak 
IgM levels observed 14-21 days post inoculation.
69
 Anti-PRRSV IgG antibodies can be 
detected by 7-10 days post infection, peak at 14-28 days post inoculation,
17
 and persist 
for up to 10 months.
70
 Antibodies specific for individual viral proteins are produced but 
not in a consistent timeframe; in one study, IgM to NSP-2 and N-protein peaked at 7 days 
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post infection with an IgG peak around 35 days, while peak levels of IgM to GP5 were 
not detected until 3-4weeks post infection.
71
 The IgG response to GP5 was also delayed, 
being first detected at 21 days and peaking at 35 days post infection, one to two weeks 
after the resolution of viremia. While serum neutralizing antibodies to GP5, GP4, and M 
protein have been reported, antibodies to GP5 are considered most effective at 
neutralizing virus.
17,72
 The role of neutralizing antibody remains unclear; studies have 
detected neutralizing antibodies along with concurrent viremia.
3,73
 In addition, several 
antibody kinetics studies have failed to detect neutralizing antibodies in PRRSV 
inoculated pigs.
69,74
 
While antibody production towards infectious agents is generally regarded as 
helpful, antibody-dependent enhancement of PRRSV infection may occur. Macrophages 
display receptors that bind antigen-antibody complexes for phagocytosis. Low levels of 
anti-PRRSV antibody may enhance the association of viral particles with pulmonary 
alveolar macrophages, leading to increased viral uptake.
44
 An in vitro study showed that 
serum containing antibodies to PRRSV actually enhanced infection of alveolar 
macrophages.
75
  
The T-cell response to PRRSV infection is first apparent around 4 weeks after 
infection where studies have demonstrated an increase in cytotoxic T-cells in the lung
76,77
 
and an increase in helper T-cells in the blood at that time.
78
 However, this is a delayed 
and relatively weak response compared to the cell-mediated immune response induced by 
other viruses.
79
 In addition, PRRSV infection results in a down-regulation of major 
histocompatibility complex expression on dendritic cells, negatively affecting the 
efficiency of antigen presentation.
80
  Protective immunity to homologous PRRSV is 
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predicated on memory cell induction. Large numbers of memory B cells are produced 
and can be found in many lymphoid tissues, particularly the spleen, tonsil, and sternal 
lymph node.
71
 Re-challenge may result in significant protection without an anamnestic 
antibody response, despite the abundance of memory B cells.
71,81
 The immunity produced 
by PRRSV infection is of long duration.
82
 However, viral persistence within the animal 
may exceed the life span of commercial pigs.
41
 
Protective immunity to heterologous PRRSV strains is highly variable due in part 
to the antigenic diversity of the virus strains. Exposure to one PRRSV strain does not 
usually confer complete protective immunity against another. In a multi-strain challenge 
study, only heterologous strains were detected in pigs after challenge; attenuated 
vaccination only provided complete protection against homologous strains.
83
 However, 
research into cross protection has found variable levels of partial protection between virus 
isolates, characterized by a reduction in clinical signs, decreased pathologic lung lesions, 
lower levels of viremia and/or increased average daily gain.  
 
Diagnostic Testing 
Due to highly variable and non-specific clinical signs, using clinical parameters 
alone to diagnose PRRSV infection is potentially inaccurate, biased, and unreliable. 
Gross and histologic changes caused by respiratory PRRSV infection are also non-
specific, and may be complicated by the presence of viral co-infections or secondary 
bacterial infections. Additional diagnostic testing is necessary to confirm PRRSV 
infection; several methods have been developed and are routinely used today. Timely and 
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accurate diagnosis is critical to the swine industry in order to limit the spread and control 
outbreaks of PRRSV. 
Most diagnostics are centered on the detection of either anti-PRRSV antibodies or 
detection of the virus itself. Antibodies to PRRSV are readily detected in serum and oral 
fluids by several methods, including serum neutralization, fluorescent focus 
neutralization, and enzyme-linked immunosorbent assay (ELISA).
84,85
 Antibody testing 
of serum merely detect animals that have been exposed to and induced an immune 
response to PRRSV. They are commonly used to monitor herds that produce PRRSV-
negative breeding animals. Immunohistochemistry (IHC) staining of formalin-fixed 
tissue uses antibody to detect viral antigen within tissue,
86
 which has the added benefit of 
associating the virus with characteristic microscopic lesions. 
Virus isolation was initially the only way of detecting PRRSV, and has been 
shown to be possible using many types of tissue infected with PRRSV including serum, 
lung, and semen. One drawback of virus isolation is that it requires live PRRSV; if the 
virus present within the sample is not viable, the test will be falsely negative. With the 
advent of polymerase chain reaction (PCR) testing, both viable and non-viable PRRSV 
can be detected through amplification of viral specific RNA. One benefit of PCR is its 
high sensitivity and specificity, and various samples can be routinely tested; viral RNA is 
commonly detected in lung tissue, organs of the immune system (tonsil and lymph 
nodes), serum, oral fluids, and semen from infected pigs.
40,87,88,89
 While PCR verifies the 
presence of viral RNA, the test does not discriminate between viable and non-viable 
PRRSV; it is simply a test for the presence or absence of PRRSV genetic material.  
14 
 
  
Sequencing of the whole viral genome as well as selected ORF segments has 
allowed for detailed genetic comparison and sorting of isolates into various classification 
schemes. Sequencing of ORF5 is the most common, and is the basis for classifying virus 
strains into lineages. Genome sequencing can also be used to determine if virus isolates 
are wild-type or vaccine-type strains, and may be used as an epidemiological tool to trace 
the spread and mutation rate of PRRSV within an endemic area. 
 
Control Strategies 
Due to the economic cost of PRRSV infection, considerable amounts of time and 
effort have been devoted to the development of various methods for the control and/or 
elimination of PRRSV. Prevention, control, and elimination of PRRSV depends on many 
factors, including the type of production system, management practices, flow of animals, 
exposure status of the site and the incoming animals, on-farm biosecurity, and goals of 
the operation. Vaccination against PRRSV is one component commonly used in several 
strategies aimed at either the control or elimination of PRRSV. 
Control of PRRSV within an endemic herd begins with stabilizing the herd 
exposure to PRRSV. An endemic herd with widespread immunity to the resident PRRSV 
strain is more likely to avoid production losses. After the entire population is protected, 
preventing the introduction of a novel strain is of utmost importance. A phylogenetic 
study of field isolates found that the most common source of new virus in a PRRSV-
positive herd was from the introduction of replacement animals carrying a new PRRSV 
strain.
90
  Prevention of PRRSV introduction through the use of PRRSV-negative semen is 
crucial; currently most boar studs have strict testing protocols in place to ensure semen is 
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PRRSV-negative. Another method for controlling PRRSV-positive herds is to 
acclimatize gilts before they are bred and introduced into the primary herd. This method 
relies on exposing gilts to the strain of PRRSV currently circulating at their eventual 
breeding farm during the growing phase, in order to stimulate a protective immune 
response that will help prevent infection, virus transmission, and reproductive failure 
upon introduction into the breeding herd.  
Elimination of PRRSV from infected herds can be costly, but has been 
accomplished through several methods.
91
 One method includes serologic testing and 
removal of all seropositive animals.
92
 Another involves the entire depopulation of a farm, 
disinfection of all facilities, and repopulation with PRRSV-negative pigs. Both of these 
methods result in the early removal of animals and loss of future production. A 
potentially less expensive method involves ceasing the introduction of new females for 
six months. Herd closure results in the exposure of all breeding females to the resident 
PRRSV strain and allows time for the development of protective immunity and eventual 
elimination of the virus. The lack of naïve, susceptible animals should result in a drastic 
reduction or elimination of the virus. Elimination methods rely on strict biosecurity to 
protect against the introduction of novel strains. The effectiveness of PRRSV elimination 
may be enhanced or adversely affected by many factors within an integrated production 
system. 
 
Vaccination 
 Various vaccination protocols have been developed in an attempt to improve 
immune protection against infection and clinical disease. While vaccination routinely 
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elicits some level of humoral and cell mediated immune response (as measured by 
neutralizing antibody and detection of interferon-gamma secreting cells),
93
 the 
effectiveness of vaccination at reducing the severity of or preventing clinical disease is 
highly variable. This variability is due in large part to genetic diversity between the 
vaccine and wild-type viruses. 
Inactivated PRRSV vaccines stimulate a very weak cell mediated immune 
response in naïve pigs,
94,95
 and have been shown to provide little to no protective 
immunity.
96
 They can be used as a booster to modified live virus (MLV) vaccination or 
intentional exposure, but are generally regarded as ineffective.
97
 Currently, there are no 
licensed commercial inactivated PRRSV vaccines in the US, but there are several 
available worldwide. While inactivated vaccines have limited practical value on their 
own, they are considered safe with almost no chance of reversion to virulence. Recent 
research into nanoparticle-bound inactivated PRRSV has shown an increased efficacy 
based on the rate of virus clearance from serum and altered cytokine expression.
98
  
 In contrast, MLV vaccines consistently elicit an immune response, including both 
humoral and cell mediated immunity, which may result in protection against clinical 
disease.
14
 Use of MLV vaccines has been shown to result in strain specific protective 
immunity,
83
 reduced clinical disease,
99,100
 and decreased viral shedding.
101
 However, 
since the vaccine uses live virus the potential for reversion to virulence exists and does 
occur.
102
 MLV vaccines have been shown to induce protective immunity against 
homologous challenge, but complete cross protection against heterologous strains has yet 
to be demonstrated. Differences in the vaccine strain used in various commercial 
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products along with diversity in regional circulating PRRSV strains may also contribute 
to the variability in effectiveness of MLV vaccination.  
Several commercial MLV vaccines are currently available in the US. Ingelvac® 
PRRS MLV (Boehringer Ingelheim Vetmedica, Inc., St. Joeseph, MO) became the first 
approved PRRSV vaccine in 1994, and is labeled for use in healthy swine as an aid in the 
reduction of disease associated with both the reproductive and respiratory forms of 
PRRSV. The parental strain of the vaccine is the North American prototype PRRSV 
strain, VR2332. Both the vaccine and the parental strain belong to lineage 5.  
Ingelvac® PRRS ATP (Boehringer Ingelheim Vetmedica, Inc., St. Joeseph, MO) 
is labeled for use as an aid in the reduction of disease associated with both forms of 
PRRSV, but is only recommended for use in PRRSV positive herds. It is a type 2 PRRSV 
vaccine belonging to lineage 8, along with its parental strain JA142. The label of both 
BIVI products claims a 4 month duration of immunity, based on internal research. 
Prime Pac™ PRRS+ (Merck Animal Health, Summit, NJ) was approved in 2014 
and is labeled for use as an aid in the reduction of clinical signs or reproductive disease 
and respiratory disease due to PRRSV. The vaccine is based on a field isolate, and the 
product label claims a 4 month duration of immunity, based on internal research. 
Fostera™ PRRS (Zoetis Animal Health US, Florham Park, NJ) is an MLV 
vaccine recently approved and currently licensed in the US and Canada. It was originally 
labeled for use in healthy swine three weeks of age or older in PRRSV-positive herds, or 
in herds deemed at risk of exposure, as an aid in preventing clinical respiratory disease 
caused by type 2 PRRSV. It was recently licensed for use in one-day old swine, as well 
as sows and gilts as an aid in preventing reproductive disease. Fostera™ PRRS is the first 
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PRRSV vaccine to earn the claim “aid in preventing” respiratory disease. The company 
claims a 6 month duration of immunity, based on internal research. The vaccine is based 
on the type 2 PRRSV strain P129, which belongs to lineage 8. 
Several novel approaches to vaccine development have recently been attempted. 
The effects of various adjuvant additions to a commercial MLV vaccine showed that IL-
12 enhanced cell mediated immunity but did not reduce clinical signs.
103
 Vectored 
vaccines using pseudorabies,
104
 adenovirus,
105
 and transmissible gastroenteritis virus
106
 to 
express PRRSV proteins have been developed. Engineered chimeric vaccines combining 
a commercial MLV vaccine and a wild-type isolate have been investigated.
107
 Several 
other vaccine platforms are under investigation, but unfortunately have yet to show 
improved efficacy over commercially available MLV vaccines.  
 
Summary of PRRSV Vaccine Challenge Studies 
 The efficacy of PRRSV vaccines and the level of cross protection they confer 
have been studied ever since the virus was first isolated. The results of these studies can 
be very difficult to interpret, for several reasons. Vaccine selection and administration 
protocols, animal selection and housing, and the selection and measurement of various 
parameters involved in immune protection can be highly variable between studies. 
Challenge virus selection can vary depending on the research group. In an attempt to 
eliminate this discrepancy and allow comparison between research trials, many studies 
use historic isolates. Due to the vast amount of antigenic drift, historic isolates may be 
considerably different genetically and phenotypically from currently circulating field 
strains, rendering the results from these challenge studies of questionable significance 
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regarding vaccine performance against contemporary strains. In addition, many studies 
have looked at vaccine induced protection against homologous challenge without 
evaluating protection against heterologous strains of virus.  
 Early vaccine research focused on viral shedding and the prevention of 
reproductive failure due to PRRSV. In one study, sows given an inactivated PRRSV 
vaccine and challenged with the homologous type 1 PRRSV strain delivered higher 
numbers of live, healthy piglets compared to unvaccinated sows.
108
 Another study found 
that boars vaccinated with an MLV vaccine had lower levels of viremia and shed less 
virus in semen than boars vaccinated with an inactivated vaccine.
109
 The inactivated 
vaccine did not decrease the level or duration of viremia or the shedding of virus in 
semen when compared to the non-vaccinated control group. Another study evaluated the 
efficacy of MLV vaccination of boars against PRRSV challenge with the type 2 
prototype strain VR-2332.
110
 Vaccination reduced or eliminated the shedding of 
challenge virus in 4 out of 5 boars; however, semen quality was negatively affected both 
after vaccination and challenge. 
Heterologous challenge studies using MLV vaccines that assess the effects of 
vaccination on respiratory disease have been reported. In one such study, two PRRSV 
field isolates from Japan were used to assess cross protection of a commercially available 
vaccine, Ingelvac PRRS MLV.
111
 One challenge virus was 94.0% similar at ORF5 to the 
vaccine strain, and vaccination resulted in reduced virus titers in lung, lymph node, and 
bronchoalveolar lavage fluid (BALF). A significant reduction in the duration of viremia 
and magnitude of gross lung lesions was also reported. The second challenge isolate was 
87.5% similar at ORF5, and vaccination had no significant effect on lung lesions or viral 
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titers in tissues or serum. However, these trials used field isolates from 2006, and 
compared data from two-to-four pigs per group in each study. 
Cross-protection induced by MLV vaccines has been studied using a wild-type 
Lelystad-like PRRSV challenge strain (98% ORF 5 homology to the vaccine strain) and a 
wild-type Italian field challenge isolate from 2001 (84% ORF5 homology).
112
 Pigs 
vaccinated with an MLV Lelystad-based vaccine were completely protected against 
challenge with the Lelystad-like virus at 49 days post vaccination, based on a lack of 
virus detection in serum and BALF. Those challenged with the Italian field isolate were 
partially protected based on lower virus titers in BALF and serum compared to 
unvaccinated pigs. Severity of lung lesions and virus levels in tissue were not assessed. 
These findings, along with those from the Japanese study, suggest that increasing 
diversity in the PRRSV genomic sequence at ORF5, when compared to the vaccine 
strain, may affect vaccine efficacy in regards to cross-protection. 
Another recent study evaluated the efficacy of Ingelvac PRRSV MLV against 
both homologous (using the type 2 prototype strain VR-2332) and heterologous challenge 
(using a field isolate from Kansas).
113
 The study reported a complete absence of viremia 
in the homologous challenge group at 7 days post challenge (dpc) along with 
significantly reduced lung lesions at necropsy; however, there was no significant decrease 
in viremia in the heterologous challenge group until 14 dpc. Pigs in the homologous 
challenge group also had significantly reduced lung lesions compared to the heterologous 
challenge group. While the study provides evidence for vaccine-induced protective 
immunity to homologous challenge, the level of protection was based on decreased lung 
scores despite the lack of negative controls for comparison. In addition, the heterologous 
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challenge virus used in the study was isolated in 2006 and data regarding ORF5 genomic 
sequence homology to the vaccine strain was not provided in the publication. 
Another study looked at the benefit of vaccination using Ingelvac PRRSV MLV 
in a herd endemically infected with a homologous strain of the virus and the response to 
heterologous challenge after different vaccination schedules.
99
 Historic PRRSV isolates 
were used as both the homologous (VR-2332) and heterologous (MN-184) challenge 
strains. Pigs were intentionally exposed to the homologous challenge virus, and then 
vaccinated according to various schedules. At 97 day after initial infection, pigs were 
challenged with the heterologous virus. The study found that exposure and vaccination 
reduced clinical signs and improved weight gain compared to unvaccinated pigs, but did 
not prevent infection with heterologous challenge virus. An assessment of lung lesions 
was not included in determining the level of protection. The study may be of limited 
value to field situations, as it would be uncommon to have a herd infected with a PRRSV 
that is homologous to the strain used in the vaccine. 
A similar study investigated the benefit of Ingelvac PRRSV MLV in a herd 
endemically infected with a heterologous strain of the virus, along with the response to 
heterologous challenge.
100
 A PRRSV field isolate was used to intentionally expose pigs, 
who were subsequently vaccinated according to various schedules. Ninety-seven days 
after initial infection with the endemic PRRSV, pigs were challenged with the historical 
isolate MN-184. Therapeutic vaccination through any of the three experimental protocols 
did not significantly reduce the viral load in tissue. However, the study found that 
previous PRRSV infection and vaccination resulted in partial protection against the 
heterologous MN-184 challenge, determined by a reduction in clinical signs, decreased 
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level of viremia, and improved growth performance. Evaluation of lung lesions and 
ORF5 sequence homology were not reported. The results suggest that a combination of 
previous exposure and vaccination to PRRSV can elicit partial protection against 
heterologous challenge. 
Intranasal delivery of a commercially available MLV vaccine has been assessed 
with subsequent heterologous challenge.
114
 The study found that intranasal vaccination of 
pigs with Ingelvac PRRSV MLV showed a reduction in clinical disease, decreased gross 
lung lesions, and a lower level of viremia at 15 days post inoculation (dpi), along with 
increased weight gain after heterologous challenge compared to unvaccinated pigs. 
However, the level of viremia was not significantly different at 30 or 60 dpi compared to 
non-vaccinated controls, and the historical isolate MN-184 was used as the challenge 
virus in this study. 
The efficacy of experimental inactivated vaccines has recently been evaluated. In 
two separate studies, pigs administered an experimental homologous inactivated vaccine 
or a commercial attenuated vaccine demonstrated a significantly shortened viremic phase 
following challenge, while a heterologous inactivated and commercial inactivated 
vaccines had no effect on viremia.
115
 While the results show some degree of partial 
protection against homologous challenge, the study reinforces previous study findings of 
the limited efficacy of inactivated vaccines compared to MLV vaccines at eliciting 
homologous protection, along with the complete lack of heterologous cross-protection 
induced by inactivated vaccines. 
Another study evaluated the protective immune response in gilts elicited by 
vaccination with a commercial inactivated PRRSV vaccine based on a Lelystad-like 
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virus.
116
 Two doses of vaccine were administered, and gilts were inoculated at 90 days 
gestation with an Italian field strain of PRRSV (no ORF5 percent homology was 
reported). Researchers found no significant difference in reproductive performance 
between vaccinated and unvaccinated gilts. In addition, the vaccine failed to prevent 
clinical signs and viremia; however, preweaning mortality was reduced, suggesting that 
even though the immune response produced through vaccination did not prevent 
infection, it may have conferred some protective benefit to the piglets. The authors 
suggest that inactivated vaccines could be used to prime the immune system to improve 
the response to a more virulent immunization/challenge later in life. 
Since PRRSV genotypes are not confined to their respective continents and can be 
found together in mixed infections, a recent study in Asia evaluated potential cross-
genotype protection of a commercially available type 1 PRRSV vaccine against a highly 
virulent type 2 field isolate.
117
 Results of the study indicate partial protection, based on a 
reduction in clinical signs and an increase in weight gain in vaccinated pigs compared to 
unvaccinated pigs. No differences in viremia were found and vaccination did not induce 
neutralizing antibodies to the challenge strain, suggesting that cell-mediated immunity 
may play an important role in the partially protective effect MLV vaccination has on 
heterologous challenge using type 1 and type 2 PRRSV vaccination and challenge 
models.  
Cell-mediated immunity was also reported as being responsible for cross 
protection in another study,
118
 where researchers used a commercially available MLV 
vaccine and a heterologous field isolate that was only 84% homologous to the vaccine 
strain at ORF5. Vaccinated pigs showed significantly reduced clinical signs and increased 
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weight gain, but failed to show a difference in viremia when compared to controls. The 
study did not investigate differences in lung lesions or viral tissue distribution. In 
addition, despite only testing the vaccine against a single virus, the authors reported that 
their results supported a previous study
119
 that suggested genetic differences or 
similarities between the challenge and vaccine viruses in the ORF5 sequence are not 
predictive of potential cross-protective immunity.  
A recent field trial investigated various clinical disease and production parameters 
in Fostera™ PRRS vaccinated pigs compared to non-vaccinated pigs on three separate 
farms.
120
 Field isolates recovered from the three farms were determined to range from 
85.4-92.2% ORF5 homology; two of the isolates belonged to lineage 5 while the other 
was a lineage 1 PRRSV. Results showed vaccinated pigs had significantly lower days to 
market, higher average daily weight gain, decreased mortality, and reduced microscopic 
lung lesions. However, the farms in the study were selected simply due to the likelihood 
of PRRSV infection, the level of viremia was not significantly different between 
vaccinated and unvaccinated pigs, and no direct challenge of pigs with a known viral 
dose occurred.  
 
Conclusion 
Due to the differences in PRRSV strains, the virus’s propensity for mutation, and 
the specificity of the immune response, heterologous challenge studies under controlled 
conditions would provide the best representation of the degree of cross protective 
immunity elicited by vaccination. Challenging vaccinated pigs with virus isolates 
currently circulating in swine would provide a better representation of potential vaccine 
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efficacy in commercial swine production than using historical isolates. In addition, 
research studies that challenge the same vaccine against several PRRSV of variable 
diversity may suggest ORF5 homology could be a useful tool in predicting the magnitude 
of potential cross-protection. To the knowledge of the author, there has been no 
heterologous challenge study reported that used a contemporary field isolate and 
demonstrated a reduction in gross and microscopic lesions, lower level of viremia, and an 
increase in average daily gain in vaccinated pigs. 
 
 
References 
 1.  Terpstra C, Wensvoort G, Pol JM Experimental reproduction of porcine epidemic 
abortion and respiratory syndrome (mystery swine disease) by infection with 
Lelystad virus: Koch's postulates fulfilled. Vet Q 13:131-6, 1991. 
 2.  Carman S, Sanford SE, Dea S Assessment of seropositivity to porcine 
reproductive and respiratory syndrome (PRRS) virus in swine herds in Ontario--
1978 to 1982. Can Vet J 36:776-7, 1995. 
 3.  Rossow KD, Bautista EM, Goyal SM, Molitor TW, Murtaugh MP, Morrison RB, 
et al. Experimental porcine reproductive and respiratory syndrome virus infection 
in one-, four-, and 10-week-old pigs. J Vet Diagn Invest 6:3-12, 1994. 
 4.  Rossow KD Porcine reproductive and respiratory syndrome. Vet Pathol 35:1-20, 
1998. 
 5.  Halbur PG, Paul PS, Frey ML, Landgraf J, Eernisse K, Meng XJ, et al. 
Comparison of the pathogenicity of two US porcine reproductive and respiratory 
syndrome virus isolates with that of the Lelystad virus. Vet Pathol 32:648-60, 
1995. 
 6.  Halbur PG, Paul PS, Meng XJ, Lum MA, Andrews JJ, Rathje JA Comparative 
pathogenicity of nine US porcine reproductive and respiratory syndrome virus 
(PRRSV) isolates in a five-week-old cesarean-derived, colostrum-deprived pig 
model. J Vet Diagn Invest 8:11-20, 1996. 
 7.  Neumann EJ, Kliebenstein JB, Johnson CD, Mabry JW, Bush EJ, Seitzinger AH, 
et al. Assessment of the economic impact of porcine reproductive and respiratory 
syndrome on swine production in the United States. J Am Vet Med Assoc 
227:385-92, 2005. 
26 
 
  
 8.  Holtkamp DJ, Kliebenstein JB, Neumann EJ, Zimmerman JJ, Rotto HF, Yoder 
TK, et al. Assessment of the economic impact of porcine reproductive and 
respiratory syndrome virus on United States pork producers. J Swine Health and 
Production 21:72-84, 2013. 
 9.  Cavanagh D Nidovirales: a new order comprising Coronaviridae and 
Arteriviridae. Arch Virol 142:629-33, 1997. 
 10.  Plagemann PG, Moennig V Lactate dehydrogenase-elevating virus, equine 
arteritis virus, and simian hemorrhagic fever virus: a new group of positive-strand 
RNA viruses. Adv Virus Res 41:99-192, 1992. 
 11.  Dokland T The structural biology of PRRSV. Virus Res 154:86-97, 2010. 
 12.  Dea S, Gagnon CA, Mardassi H, Pirzadeh B, Rogan D Current knowledge on the 
structural proteins of porcine reproductive and respiratory syndrome (PRRS) 
virus: comparison of the North American and European isolates. Arch Virol 
145:659-88, 2000. 
 13.  Murtaugh MP, Elam MR, Kakach LT Comparison of the structural protein coding 
sequences of the VR-2332 and Lelystad virus strains of the PRRS virus. Arch 
Virol 140:1451-60, 1995. 
 14.  Meng XJ Heterogeneity of porcine reproductive and respiratory syndrome virus: 
implications for current vaccine efficacy and future vaccine development. Vet 
Microbiol 74:309-29, 2000. 
 15.  Gonin P, Pirzadeh B, Gagnon CA, Dea S Seroneutralization of porcine 
reproductive and respiratory syndrome virus correlates with antibody response to 
the GP5 major envelope glycoprotein. J Vet Diagn Invest 11:20-6, 1999. 
 16.  Yang L, Frey ML, Yoon KJ, Zimmerman JJ, Platt KB Categorization of North 
American porcine reproductive and respiratory syndrome viruses: epitopic 
profiles of the N, M, GP5 and GP3 proteins and susceptibility to neutralization. 
Arch Virol 145:1599-619, 2000. 
 17.  Yoon KJ, Zimmerman JJ, Swenson SL, McGinley MJ, Eernisse KA, Brevik A, et 
al. Characterization of the humoral immune response to porcine reproductive and 
respiratory syndrome (PRRS) virus infection. J Vet Diagn Invest 7:305-12, 1995. 
 18.  Meng XJ, Paul PS, Halbur PG, Lum MA Phylogenetic analyses of the putative M 
(ORF 6) and N (ORF 7) genes of porcine reproductive and respiratory syndrome 
virus (PRRSV): implication for the existence of two genotypes of PRRSV in the 
U.S.A. and Europe. Arch Virol 140:745-55, 1995. 
 19.  Delputte PL, Vanderheijden N, Nauwynck HJ, Pensaert MB Involvement of the 
matrix protein in attachment of porcine reproductive and respiratory syndrome 
27 
 
  
virus to a heparinlike receptor on porcine alveolar macrophages. J Virol 76:4312-
20, 2002. 
 20.  Delputte PL, Nauwynck HJ Porcine arterivirus infection of alveolar macrophages 
is mediated by sialic acid on the virus. J Virol 78:8094-101, 2004. 
 21.  Delputte PL, Costers S, Nauwynck HJ Analysis of porcine reproductive and 
respiratory syndrome virus attachment and internalization: distinctive roles for 
heparan sulphate and sialoadhesin. J Gen Virol 86:1441-5, 2005. 
 22.  Wissink EH, Kroese MV, van Wijk HA, Rijsewijk FA, Meulenberg JJ, Rottier PJ 
Envelope protein requirements for the assembly of infectious virions of porcine 
reproductive and respiratory syndrome virus. J Virol 79:12495-506, 2005. 
 23.  Murtaugh MP, Xiao Z, Zuckermann F Immunological responses of swine to 
porcine reproductive and respiratory syndrome virus infection. Viral Immunol 
15:533-47, 2002. 
 24.  Duan X, Nauwynck HJ, Pensaert MB Virus quantification and identification of 
cellular targets in the lungs and lymphoid tissues of pigs at different time intervals 
after inoculation with porcine reproductive and respiratory syndrome virus 
(PRRSV). Vet Microbiol 56:9-19, 1997. 
 25.  Kim HS, Kwang J, Yoon IJ, Joo HS, Frey ML Enhanced replication of porcine 
reproductive and respiratory syndrome (PRRS) virus in a homogeneous 
subpopulation of MA-104 cell line. Arch Virol 133:477-83, 1993. 
 26.  Mengeling WL, Lager KM, Vorwald AC Diagnosis of porcine reproductive and 
respiratory syndrome. J Vet Diagn Invest 7:3-16, 1995. 
 27.  Van BW, Delputte PL, Van GH, Misinzo G, Vanderheijden N, Duan X, et al. 
Porcine reproductive and respiratory syndrome virus entry into the porcine 
macrophage. J Gen Virol 91:1659-67, 2010. 
 28.  Duan X, Nauwynck HJ, Favoreel H, Pensaert MB Porcine reproductive and 
respiratory syndrome virus infection of alveolar macrophages can be blocked by 
monoclonal antibodies against cell surface antigens. Adv Exp Med Biol 440:81-8, 
1998. 
 29.  Duan X, Nauwynck HJ, Favoreel HW, Pensaert MB Identification of a putative 
receptor for porcine reproductive and respiratory syndrome virus on porcine 
alveolar macrophages. J Virol 72:4520-3, 1998. 
 30.  Vanderheijden N, Delputte PL, Favoreel HW, Vandekerckhove J, Van DJ, van 
Woensel PA, et al. Involvement of sialoadhesin in entry of porcine reproductive 
and respiratory syndrome virus into porcine alveolar macrophages. J Virol 
77:8207-15, 2003. 
28 
 
  
 31.  Calvert JG, Slade DE, Shields SL, Jolie R, Mannan RM, Ankenbauer RG, et al. 
CD163 expression confers susceptibility to porcine reproductive and respiratory 
syndrome viruses. J Virol 81:7371-9, 2007. 
 32.  Van GH, Van BW, Delputte PL, Nauwynck HJ Sialoadhesin and CD163 join 
forces during entry of the porcine reproductive and respiratory syndrome virus. J 
Gen Virol 89:2943-53, 2008. 
 33.  Misinzo GM, Delputte PL, Nauwynck HJ Involvement of proteases in porcine 
reproductive and respiratory syndrome virus uncoating upon internalization in 
primary macrophages. Vet Res 39:55, 2008. 
 34.  Miller LC, Fox JM Apoptosis and porcine reproductive and respiratory syndrome 
virus. Vet Immunol Immunopathol 102:131-42, 2004. 
 35.  De Baere MI, Van GH, Delputte PL, Nauwynck HJ Interaction of the European 
genotype porcine reproductive and respiratory syndrome virus (PRRSV) with 
sialoadhesin (CD169/Siglec-1) inhibits alveolar macrophage phagocytosis. Vet 
Res 43:47, 2012. 
 36.  Thanawongnuwech R, Young TF, Thacker BJ, Thacker EL Differential 
production of proinflammatory cytokines: in vitro PRRSV and Mycoplasma 
hyopneumoniae co-infection model. Vet Immunol Immunopathol 79:115-27, 
2001. 
 37.  Costers S, Lefebvre DJ, Delputte PL, Nauwynck HJ Porcine reproductive and 
respiratory syndrome virus modulates apoptosis during replication in alveolar 
macrophages. Arch Virol 153:1453-65, 2008. 
 38.  Lamontagne L, Page C, Larochelle R, Magar R Porcine reproductive and 
respiratory syndrome virus persistence in blood, spleen, lymph nodes, and tonsils 
of experimentally infected pigs depends on the level of CD8high T cells. Viral 
Immunol 16:395-406, 2003. 
 39.  Xiao Z, Batista L, Dee S, Halbur P, Murtaugh MP The level of virus-specific T-
cell and macrophage recruitment in porcine reproductive and respiratory 
syndrome virus infection in pigs is independent of virus load. J Virol 78:5923-33, 
2004. 
 40.  Wills RW, Doster AR, Galeota JA, Sur JH, Osorio FA Duration of infection and 
proportion of pigs persistently infected with porcine reproductive and respiratory 
syndrome virus. J Clin Microbiol 41:58-62, 2003. 
 41.  Rowland RR, Lawson S, Rossow K, Benfield DA Lymphoid tissue tropism of 
porcine reproductive and respiratory syndrome virus replication during persistent 
infection of pigs originally exposed to virus in utero. Vet Microbiol 96:219-35, 
2003. 
29 
 
  
 42.  Van RK, Labarque G, Nauwynck H, Pensaert M Differential production of 
proinflammatory cytokines in the pig lung during different respiratory virus 
infections: correlations with pathogenicity. Res Vet Sci 67:47-52, 1999. 
 43.  Costers S, Delputte PL, Nauwynck HJ Porcine reproductive and respiratory 
syndrome virus-infected alveolar macrophages contain no detectable levels of 
viral proteins in their plasma membrane and are protected against antibody-
dependent, complement-mediated cell lysis. J Gen Virol 87:2341-51, 2006. 
 44.  Yoon KJ, Wu LL, Zimmerman JJ, Platt KB Field isolates of porcine reproductive 
and respiratory syndrome virus (PRRSV) vary in their susceptibility to antibody 
dependent enhancement (ADE) of infection. Vet Microbiol 55:277-87, 1997. 
 45.  Done SH, Paton DJ Porcine reproductive and respiratory syndrome: clinical 
disease, pathology and immunosuppression. Vet Rec 136:32-5, 1995. 
 46.  Rossow KD, Collins JE, Goyal SM, Nelson EA, Christopher-Hennings J, 
Benfield DA Pathogenesis of porcine reproductive and respiratory syndrome virus 
infection in gnotobiotic pigs. Vet Pathol 32:361-73, 1995. 
 47.  Christianson WT, Collins JE, Benfield DA, Harris L, Gorcyca DE, Chladek DW, 
et al. Experimental reproduction of swine infertility and respiratory syndrome in 
pregnant sows. Am J Vet Res 53:485-8, 1992. 
 48.  Forsberg R Divergence time of porcine reproductive and respiratory syndrome 
virus subtypes. Mol Biol Evol 22:2131-4, 2005. 
 49.  Kapur V, Elam MR, Pawlovich TM, Murtaugh MP Genetic variation in porcine 
reproductive and respiratory syndrome virus isolates in the midwestern United 
States. J Gen Virol 77 ( Pt 6):1271-6, 1996. 
 50.  Nelsen CJ, Murtaugh MP, Faaberg KS Porcine reproductive and respiratory 
syndrome virus comparison: divergent evolution on two continents. J Virol 
73:270-80, 1999. 
 51.  Wensvoort G, De Kluyver EP, Luijtze EA, den BA, Harris L, Collins JE, et al. 
Antigenic comparison of Lelystad virus and swine infertility and respiratory 
syndrome (SIRS) virus. J Vet Diagn Invest 4:134-8, 1992. 
 52.  Murtaugh MP, Stadejek T, Abrahante JE, Lam TT, Leung FC The ever-expanding 
diversity of porcine reproductive and respiratory syndrome virus. Virus Res 
154:18-30, 2010. 
 53.  Wesley RD, Mengeling WL, Lager KM, Clouser DF, Landgraf JG, Frey ML 
Differentiation of a porcine reproductive and respiratory syndrome virus vaccine 
strain from North American field strains by restriction fragment length 
polymorphism analysis of ORF 5. J Vet Diagn Invest 10:140-4, 1998. 
30 
 
  
 54.  Wesley RD, Mengeling WL, Lager KM, Vorwald AC, Roof MB Evidence for 
divergence of restriction fragment length polymorphism patterns following in 
vivo replication of porcine reproductive and respiratory syndrome virus. Am J Vet 
Res 60:463-7, 1999. 
 55.  Cha SH, Chang CC, Yoon KJ Instability of the restriction fragment length 
polymorphism pattern of open reading frame 5 of porcine reproductive and 
respiratory syndrome virus during sequential pig-to-pig passages. J Clin 
Microbiol 42:4462-7, 2004. 
 56.  Shi M, Lam TT, Hon CC, Murtaugh MP, Davies PR, Hui RK, et al. Phylogeny-
based evolutionary, demographical, and geographical dissection of North 
American type 2 porcine reproductive and respiratory syndrome viruses. J Virol 
84:8700-11, 2010. 
 57.  Hanada K, Suzuki Y, Nakane T, Hirose O, Gojobori T The origin and evolution 
of porcine reproductive and respiratory syndrome viruses. Mol Biol Evol 
22:1024-31, 2005. 
 58.  van Vugt JJ, Storgaard T, Oleksiewicz MB, Botner A High frequency RNA 
recombination in porcine reproductive and respiratory syndrome virus occurs 
preferentially between parental sequences with high similarity. J Gen Virol 
82:2615-20, 2001. 
 59.  Yuan S, Nelsen CJ, Murtaugh MP, Schmitt BJ, Faaberg KS Recombination 
between North American strains of porcine reproductive and respiratory 
syndrome virus. Virus Res 61:87-98, 1999. 
 60.  Franca R, Spadari S, Maga G APOBEC deaminases as cellular antiviral factors: a 
novel natural host defense mechanism. Med Sci Monit 12:RA92-RA98, 2006. 
 61.  Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, 
et al. Biological properties of recombinant alpha-interferons: 40th anniversary of 
the discovery of interferons. Cancer Res 58:2489-99, 1998. 
 62.  Albina E, Carrat C, Charley B Interferon-alpha response to swine arterivirus 
(PoAV), the porcine reproductive and respiratory syndrome virus. J Interferon 
Cytokine Res 18:485-90, 1998. 
 63.  Buddaert W, Van RK, Pensaert M In vivo and in vitro interferon (IFN) studies 
with the porcine reproductive and respiratory syndrome virus (PRRSV). Adv Exp 
Med Biol 440:461-7, 1998. 
 64.  Lee SM, Schommer SK, Kleiboeker SB Porcine reproductive and respiratory 
syndrome virus field isolates differ in in vitro interferon phenotypes. Vet 
Immunol Immunopathol 102:217-31, 2004. 
31 
 
  
 65.  Tay CH, Szomolanyi-Tsuda E, Welsh RM Control of infections by NK cells. Curr 
Top Microbiol Immunol 230:193-220, 1998. 
 66.  Choi C, Cho WS, Kim B, Chae C Expression of Interferon-gamma and tumour 
necrosis factor-alpha in pigs experimentally infected with Porcine Reproductive 
and Respiratory Syndrome Virus (PRRSV). J Comp Pathol 127:106-13, 2002. 
 67.  Suradhat S, Thanawongnuwech R Upregulation of interleukin-10 gene expression 
in the leukocytes of pigs infected with porcine reproductive and respiratory 
syndrome virus. J Gen Virol 84:2755-60, 2003. 
 68.  Thanawongnuwech R, Rungsipipat A, Disatian S, Saiyasombat R, Napakanaporn 
S, Halbur PG Immunohistochemical staining of IFN-gamma positive cells in 
porcine reproductive and respiratory syndrome virus-infected lungs. Vet Immunol 
Immunopathol 91:73-7, 2003. 
 69.  Loemba HD, Mounir S, Mardassi H, Archambault D, Dea S Kinetics of humoral 
immune response to the major structural proteins of the porcine reproductive and 
respiratory syndrome virus. Arch Virol 141:751-61, 1996. 
 70.  Nielsen J, Botner A Hematological and immunological parameters of 4 1/2-month 
old pigs infected with PRRS virus. Vet Microbiol 55:289-94, 1997. 
 71.  Mulupuri P, Zimmerman JJ, Hermann J, Johnson CR, Cano JP, Yu W, et al. 
Antigen-specific B-cell responses to porcine reproductive and respiratory 
syndrome virus infection. J Virol 82:358-70, 2008. 
 72.  Weiland E, Wieczorek-Krohmer M, Kohl D, Conzelmann KK, Weiland F 
Monoclonal antibodies to the GP5 of porcine reproductive and respiratory 
syndrome virus are more effective in virus neutralization than monoclonal 
antibodies to the GP4. Vet Microbiol 66:171-86, 1999. 
 73.  Wills RW, Zimmerman JJ, Yoon KJ, Swenson SL, McGinley MJ, Hill HT, et al. 
Porcine reproductive and respiratory syndrome virus: a persistent infection. Vet 
Microbiol 55:231-40, 1997. 
 74.  Nelson EA, Christopher-Hennings J, Benfield DA Serum immune responses to 
the proteins of porcine reproductive and respiratory syndrome (PRRS) virus. J Vet 
Diagn Invest 6:410-5, 1994. 
 75.  Yoon KJ, Wu LL, Zimmerman JJ, Hill HT, Platt KB Antibody-dependent 
enhancement (ADE) of porcine reproductive and respiratory syndrome virus 
(PRRSV) infection in pigs. Viral Immunol 9:51-63, 1996. 
 76.  Samsom JN, de Bruin TG, Voermans JJ, Meulenberg JJ, Pol JM, Bianchi AT 
Changes of leukocyte phenotype and function in the broncho-alveolar lavage fluid 
of pigs infected with porcine reproductive and respiratory syndrome virus: a role 
for CD8(+) cells. J Gen Virol 81:497-505, 2000. 
32 
 
  
 77.  Shimizu M, Yamada S, Kawashima K, Ohashi S, Shimizu S, Ogawa T Changes 
of lymphocyte subpopulations in pigs infected with porcine reproductive and 
respiratory syndrome (PRRS) virus. Vet Immunol Immunopathol 50:19-27, 1996. 
 78.  Bautista EM, Molitor TW Cell-mediated immunity to porcine reproductive and 
respiratory syndrome virus in swine. Viral Immunol 10:83-94, 1997. 
 79.  Meier WA, Galeota J, Osorio FA, Husmann RJ, Schnitzlein WM, Zuckermann 
FA Gradual development of the interferon-gamma response of swine to porcine 
reproductive and respiratory syndrome virus infection or vaccination. Virology 
309:18-31, 2003. 
 80.  Wang X, Eaton M, Mayer M, Li H, He D, Nelson E, et al. Porcine reproductive 
and respiratory syndrome virus productively infects monocyte-derived dendritic 
cells and compromises their antigen-presenting ability. Arch Virol 152:289-303, 
2007. 
 81.  Foss DL, Zilliox MJ, Meier W, Zuckermann F, Murtaugh MP Adjuvant danger 
signals increase the immune response to porcine reproductive and respiratory 
syndrome virus. Viral Immunol 15:557-66, 2002. 
 82.  Lager KM, Mengeling WL, Brockmeier SL Duration of homologous porcine 
reproductive and respiratory syndrome virus immunity in pregnant swine. Vet 
Microbiol 58:127-33, 1997. 
 83.  Mengeling WL, Lager KM, Vorwald AC, Koehler KJ Strain specificity of the 
immune response of pigs following vaccination with various strains of porcine 
reproductive and respiratory syndrome virus. Vet Microbiol 93:13-24, 2003. 
 84.  Albina E, Leforban Y, Baron T, Plana Duran JP, Vannier P An enzyme linked 
immunosorbent assay (ELISA) for the detection of antibodies to the porcine 
reproductive and respiratory syndrome (PRRS) virus. Ann Rech Vet 23:167-76, 
1992. 
 85.  Prickett JR, Zimmerman JJ The development of oral fluid-based diagnostics and 
applications in veterinary medicine. Anim Health Res Rev 11:207-16, 2010. 
 86.  Halbur PG, Andrews JJ, Huffman EL, Paul PS, Meng XJ, Niyo Y Development 
of a streptavidin-biotin immunoperoxidase procedure for the detection of porcine 
reproductive and respiratory syndrome virus antigen in porcine lung. J Vet Diagn 
Invest 6:254-7, 1994. 
 87.  Bierk MD, Dee SA, Rossow KD, Collins JE, Guedes MI, Pijoan C, et al. 
Diagnostic investigation of chronic porcine reproductive and respiratory 
syndrome virus in a breeding herd of pigs. Vet Rec 148:687-90, 2001. 
33 
 
  
 88.  Christopher-Hennings J, Nelson EA PCR analysis for the identification of porcine 
reproductive and respiratory syndrome virus in boar semen. Methods Mol Biol 
92:81-8, 1998. 
 89.  Prickett J, Simer R, Christopher-Hennings J, Yoon KJ, Evans RB, Zimmerman JJ 
Detection of Porcine reproductive and respiratory syndrome virus infection in 
porcine oral fluid samples: a longitudinal study under experimental conditions. J 
Vet Diagn Invest 20:156-63, 2008. 
 90.  Pesente P, Rebonato V, Sandri G, Giovanardi D, Ruffoni LS, Torriani S 
Phylogenetic analysis of ORF5 and ORF7 sequences of porcine reproductive and 
respiratory syndrome virus (PRRSV) from PRRS-positive Italian farms: a 
showcase for PRRSV epidemiology and its consequences on farm management. 
Vet Microbiol 114:214-24, 2006. 
 91.  Corzo CA, Mondaca E, Wayne S, Torremorell M, Dee S, Davies P, et al. Control 
and elimination of porcine reproductive and respiratory syndrome virus. Virus 
Res 154:185-92, 2010. 
 92.  Dee SA, Bierk MD, Deen J, Molitor TW An evaluation of test and removal for 
the elimination of porcine reproductive and respiratory syndrome virus from 5 
swine farms. Can J Vet Res 65:22-7, 2001. 
 93.  Diaz I, Gimeno M, Callen A, Pujols J, Lopez S, Charreyre C, et al. Comparison of 
different vaccination schedules for sustaining the immune response against 
porcine reproductive and respiratory syndrome virus. Vet J 197:438-44, 2013. 
 94.  Bassaganya-Riera J, Thacker BJ, Yu S, Strait E, Wannemuehler MJ, Thacker EL 
Impact of immunizations with porcine reproductive and respiratory syndrome 
virus on lymphoproliferative recall responses of CD8+ T cells. Viral Immunol 
17:25-37, 2004. 
 95.  Piras F, Bollard S, Laval F, Joisel F, Reynaud G, Charreyre C, et al. Porcine 
reproductive and respiratory syndrome (PRRS) virus-specific interferon-
gamma(+) T-cell responses after PRRS virus infection or vaccination with an 
inactivated PRRS vaccine. Viral Immunol 18:381-9, 2005. 
 96.  Zuckermann FA, Garcia EA, Luque ID, Christopher-Hennings J, Doster A, Brito 
M, et al. Assessment of the efficacy of commercial porcine reproductive and 
respiratory syndrome virus (PRRSV) vaccines based on measurement of serologic 
response, frequency of gamma-IFN-producing cells and virological parameters of 
protection upon challenge. Vet Microbiol 123:69-85, 2007. 
 97.  Nilubol D, Platt KB, Halbur PG, Torremorell M, Harris DL The effect of a killed 
porcine reproductive and respiratory syndrome virus (PRRSV) vaccine treatment 
on virus shedding in previously PRRSV infected pigs. Vet Microbiol 102:11-8, 
2004. 
34 
 
  
 98.  Binjawadagi B, Dwivedi V, Manickam C, Ouyang K, Wu Y, Lee LJ, et al. 
Adjuvanted poly(lactic-co-glycolic) acid nanoparticle-entrapped inactivated 
porcine reproductive and respiratory syndrome virus vaccine elicits cross-
protective immune response in pigs. Int J Nanomedicine 9:679-94, 2014. 
 99.  Cano JP, Dee SA, Murtaugh MP, Trincado CA, Pijoan CB Effect of vaccination 
with a modified-live porcine reproductive and respiratory syndrome virus vaccine 
on dynamics of homologous viral infection in pigs. Am J Vet Res 68:565-71, 
2007. 
 100.  Cano JP, Dee SA, Murtaugh MP, Pijoan C Impact of a modified-live porcine 
reproductive and respiratory syndrome virus vaccine intervention on a population 
of pigs infected with a heterologous isolate. Vaccine 25:4382-91, 2007. 
 101.  Linhares DC, Cano JP, Wetzell T, Nerem J, Torremorell M, Dee SA Effect of 
modified-live porcine reproductive and respiratory syndrome virus (PRRSv) 
vaccine on the shedding of wild-type virus from an infected population of 
growing pigs. Vaccine 30:407-13, 2012. 
 102.  Botner A, Strandbygaard B, Sorensen KJ, Have P, Madsen KG, Madsen ES, et al. 
Appearance of acute PRRS-like symptoms in sow herds after vaccination with a 
modified live PRRS vaccine. Vet Rec 141:497-9, 1997. 
 103.  Charerntantanakul W, Platt R, Johnson W, Roof M, Vaughn E, Roth JA Immune 
responses and protection by vaccine and various vaccine adjuvant candidates to 
virulent porcine reproductive and respiratory syndrome virus. Vet Immunol 
Immunopathol 109:99-115, 2006. 
 104.  Qiu HJ, Tian ZJ, Tong GZ, Zhou YJ, Ni JQ, Luo YZ, et al. Protective immunity 
induced by a recombinant pseudorabies virus expressing the GP5 of porcine 
reproductive and respiratory syndrome virus in piglets. Vet Immunol 
Immunopathol 106:309-19, 2005. 
 105.  Jiang W, Jiang P, Wang X, Li Y, Du Y, Wang X Enhanced immune responses of 
mice inoculated recombinant adenoviruses expressing GP5 by fusion with GP3 
and/or GP4 of PRRS virus. Virus Res 136:50-7, 2008. 
 106.  Cruz JL, Zuniga S, Becares M, Sola I, Ceriani JE, Juanola S, et al. Vectored 
vaccines to protect against PRRSV. Virus Res 154:150-60, 2010. 
 107.  Ellingson JS, Wang Y, Layton S, Ciacci-Zanella J, Roof MB, Faaberg KS 
Vaccine efficacy of porcine reproductive and respiratory syndrome virus 
chimeras. Vaccine 28:2679-86, 2010. 
 108.  Plana-Duran J, Bastons M, Urniza A, Vayreda M, Vila X, Mane H Efficacy of an 
inactivated vaccine for prevention of reproductive failure induced by porcine 
reproductive and respiratory syndrome virus. Vet Microbiol 55:361-70, 1997. 
35 
 
  
 109.  Nielsen TL, Nielsen J, Have P, Baekbo P, Hoff-Jorgensen R, Botner A 
Examination of virus shedding in semen from vaccinated and from previously 
infected boars after experimental challenge with porcine reproductive and 
respiratory syndrome virus. Vet Microbiol 54:101-12, 1997. 
 110.  Christopher-Hennings J, Nelson EA, Nelson JK, Benfield DA Effects of a 
modified-live virus vaccine against porcine reproductive and respiratory 
syndrome in boars. Am J Vet Res 58:40-5, 1997. 
 111.  Okuda Y, Kuroda M, Ono M, Chikata S, Shibata I Efficacy of vaccination with 
porcine reproductive and respiratory syndrome virus following challenges with 
field isolates in Japan. J Vet Med Sci 70:1017-25, 2008. 
 112.  Labarque G, Reeth KV, Nauwynck H, Drexler C, Van GS, Pensaert M Impact of 
genetic diversity of European-type porcine reproductive and respiratory syndrome 
virus strains on vaccine efficacy. Vaccine 22:4183-90, 2004. 
 113.  Li X, Galliher-Beckley A, Pappan L, Trible B, Kerrigan M, Beck A, et al. 
Comparison of host immune responses to homologous and heterologous type II 
porcine reproductive and respiratory syndrome virus (PRRSV) challenge in 
vaccinated and unvaccinated pigs. Biomed Res Int 2014:416727, 2014. 
 114.  Dwivedi V, Manickam C, Patterson R, Dodson K, Murtaugh M, Torrelles JB, et 
al. Cross-protective immunity to porcine reproductive and respiratory syndrome 
virus by intranasal delivery of a live virus vaccine with a potent adjuvant. Vaccine 
29:4058-66, 2011. 
 115.  Geldhof MF, Vanhee M, Van BW, Van DJ, Karniychuk UU, Nauwynck HJ 
Comparison of the efficacy of autogenous inactivated Porcine Reproductive and 
Respiratory Syndrome Virus (PRRSV) vaccines with that of commercial vaccines 
against homologous and heterologous challenges. BMC Vet Res 8:182, 2012. 
 116.  Scortti M, Prieto C, Alvarez E, Simarro I, Castro JM Failure of an inactivated 
vaccine against porcine reproductive and respiratory syndrome to protect gilts 
against a heterologous challenge with PRRSV. Vet Rec 161:809-13, 2007. 
 117.  Roca M, Gimeno M, Bruguera S, Segales J, Diaz I, Galindo-Cardiel IJ, et al. 
Effects of challenge with a virulent genotype II strain of porcine reproductive and 
respiratory syndrome virus on piglets vaccinated with an attenuated genotype I 
strain vaccine. Vet J 193:92-6, 2012. 
 118.  Martelli P, Gozio S, Ferrari L, Rosina S, De AE, Quintavalla C, et al. Efficacy of 
a modified live porcine reproductive and respiratory syndrome virus (PRRSV) 
vaccine in pigs naturally exposed to a heterologous European (Italian cluster) 
field strain: Clinical protection and cell-mediated immunity. Vaccine 27:3788-99, 
2009. 
36 
 
  
 119.  Prieto C, Alvarez E, Martinez-Lobo FJ, Simarro I, Castro JM Similarity of 
European porcine reproductive and respiratory syndrome virus strains to vaccine 
strain is not necessarily predictive of the degree of protective immunity conferred. 
Vet J 175:356-63, 2008. 
 120.  Park C, Seo HW, Kang I, Jeong J, Choi K, Chae C A new modified live porcine 
reproductive and respiratory syndrome vaccine improves growth performance in 
pigs under field conditions. Clin Vaccine Immunol 21:1350-6, 2014. 
 
 
  
37 
 
  
CHAPTER 3: EVALUATION OF CROSS-PROTECTION IN FOSTERA™ PRRS 
VACCINATED NURSERY SWINE CHALLENGED WITH A 
CONTEMPORARY, HETEROLOGOUS LINEAGE 9 PORCINE 
REPRODUCTIVE AND RESPIRATORYSYNDROME VIRUS 
 
 
Prepared for submission for publication 
 
 
Running title: Cross-protection in PRRSV vaccinated swine challenged with a lineage 9 
virus. 
 
 
Drew Magstadt,
1
 Jianqiang Zhang,
1
 Jesse Hostetter,
2
 Darin M. Madson,
1
  
Eric Burrough,
1
 Paulo H.E. Arruda,
1
 Angela Pillatzki,
3
 Karen Harmon,
1
  
Chong Wang,
1,4
 Phillip C. Gauger
1# 
 
 
1
Department of Veterinary Diagnostic and Production Animal Medicine, College of 
Veterinary Medicine, Iowa State University, Ames, IA 50011, USA 
2
Department of Veterinary Pathology, College of Veterinary Medicine,  
Iowa State University, Ames, IA 50011, USA 
3
Veterinary and Biomedical Sciences, South Dakota State University,  
Brookings, SD 57007, USA 
4
Department of Statistics, Iowa State University, Ames, IA, 50011, USA 
 
#Corresponding author. Mailing address: 1575 Vet Med, Iowa State University, 1600 
South 16
th
 Street, Ames, IA, 50011, USA. Phone: (515) 294-2437. Fax: (515) 294-3564. 
E-mail: pcgauger@iastate.edu. 
 
Abstract 
Porcine reproductive and respiratory syndrome virus currently circulating in 
swine demonstrates marked genetic diversity and forms multiple phylogenetic lineages. 
Modified live PRRSV vaccines have been used in intervention strategies to provide 
protection against infection and reduce the impact of clinical disease. Prevention and 
control of the virus has become challenging due to antigenic differences observed in 
contemporary PRRSV isolated from swine. The objective of this study was to evaluate 
38 
 
  
the efficacy of Fostera™ PRRS vaccine administered to weaned pigs against challenge 
with a contemporary, heterologous lineage 9 PRRSV. The challenge virus 12-39404 was 
isolated from nursery pigs in 2012 and shared 92% ORF5 nucleotide homology with the 
Fostera™ PRRS vaccine virus. Magnitude of gross and microscopic lung lesions at 12 
days post infection were significantly lower in pigs that received Fostera™ PRRS 
compared to the non-vaccinated and challenged group. Viremia at 7 and 12 days post 
infection was also significantly lower in pigs that received Fostera™ PRRS and challenge 
virus was detected at significantly lower quantities in lung and bronchoalveolar lavage 
fluid compared to non-vaccinated and challenged pigs at necropsy. Vaccinated pigs also 
demonstrated improved average daily gain during the post-vaccination period concurrent 
with mild respiratory clinical signs. These results suggest Fostera™ PRRS induced 
partial cross-protection against a heterologous PRRSV recently isolated from swine and 
may represent outcomes that could be expected in current field infections with a 
contemporary lineage 9 PRRSV. 
 
Introduction 
Porcine reproductive and respiratory syndrome (PRRS), characterized by 
reproductive failure or abortion in sows and respiratory disease in growing pigs, is caused 
by PRRS virus (PRRSV) that was initially isolated in the United States (US) in 1990.
1
 
PRRSV is a positive sense, enveloped, single-stranded RNA virus of the family 
Arteriviridae in the order Nidovirales.
2
 The virus is ubiquitous in swine throughout the 
world and has been estimated to cost the US swine industry approximately $664 million 
annually.
3,4,5
 Effects in growing pigs account for 55% of these losses, mostly attributed to 
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increased mortality and elevated feed costs due to decreased feed efficiency.
4
 Infection 
with PRRSV commonly results in interstitial pneumonia, but has also been shown to have 
immunosuppressive effects leading to increased susceptibility to infection with other 
swine pathogens.
6
 
Two predominant PRRSV genotypes circulate in swine and are recognized as the 
European type 1 (strain Lelystad) and the North American type 2 genotypes (strain VR-
2332).
7,8
 However, PRRSV currently circulating in US swine, regardless of genotype, are 
genetically and antigenically diverse. The virus has rapidly evolved through genetic 
mutation, recombination and redistribution throughout swine-producing 
regions.
5,9,10,11,12,13
 Phylogenetic analysis has also classified PRRSV into nine lineages 
and multiple sublineages representing immense differences in the genetic content and 
potential antigenic properties of the virus.
5
 Lineage 1 PRRSV includes the RFLP pattern 
1-8-4 that became prevalent in the early 2000’s. Lineage 8 and 9 PRRSV were 
responsible for several field outbreaks involving abortion storms described in 1996 and 
includes the NADC20 isolate.
5,14
 Currently, swine producers are encouraged to monitor 
the genotype of PRRSV circulating in their herd as well as swine producing regions, to 
detect the introduction of a new, antigenically distinct PRRSV. 
Modified live and inactivated PRRSV vaccines have been used for the prevention 
and control of the virus with the goal of reducing the number of susceptible animals in 
the breeding herd, facilitating the production of negative piglets and preventing 
respiratory disease and production losses in grow-finish swine.
15
 Inactivated PRRSV 
vaccines are less efficacious compared to PRRS modified-live virus (MLV) products.
16
 
Vaccination with PRRS MLV has demonstrated more effective control at reducing 
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clinical signs, decreasing lung lesions and viremia following challenge with homologous 
PRRSV; however, protection against heterologous infection is often 
inadequate.
17,18,19,20,21
 A recent report demonstrated Fostera™ PRRS vaccinated pigs had 
increased average daily gain, decreased mortality and lower microscopic lung lesions 
compared to non-vaccinated swine when pigs were naturally exposed to the virus.
22
 
However, the study failed to show a significant decrease in viremia in vaccinated pigs 
and did not evaluate similar parameters using a heterologous challenge model under 
experimental conditions.  
Experimental vaccine studies often use historical PRRSV isolates as challenge 
virus that may not be representative of the genetically diverse viruses currently 
circulating in the swine population.
20,23,24
 Additional vaccine/challenge studies are needed 
using contemporary PRRSV that may represent potential cross-protection experienced 
under field conditions. Therefore, a lineage 9 heterologous PRRSV isolate was selected 
as the challenge inoculum from a field infection diagnosed in nursery pigs in 2012.  The 
objectives of this study were to assess the magnitude of cross-protection induced by 
Fostera™ PRRS vaccine by comparing the level of viremia, gross and microscopic lung 
lesions, and average daily gain in vaccinated and non-vaccinated growing pigs challenged 
with a contemporary, heterologous lineage 9 PRRSV field isolate.  
 
Materials and Methods 
Animals 
Sixty-two, four-week-old male, non-vaccinated weaned pigs were sourced from a 
single commercial, cross-bred farrow-to-wean herd. Upon arrival, all pigs were tested via 
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PCR for PRRSV and porcine circovirus type 2 (PCV2) in serum and influenza A virus 
(IAV) and Mycoplasma hyopneumoniae (MHP) in nasal swabs.  Pigs were tested for the 
presence of antibody to PRRSV, IAV, PCV2, and MHP in serum prior to the start of the 
trial. All pigs were administered an intramuscular (IM) injection of ceftiofur crystalline 
free acid (Excede®, Zoetis, Florham Park, NJ) per label instructions upon arrival to the 
research facility and one day prior to challenge, and one IM injection of enrofloxacin 
(Baytril®, Bayer Healthcare, LLC, Shawnee Mission, KS) one day prior to vaccination to 
reduce potential mortality due to secondary bacterial infections common in swine.   
 
PRRSV challenge virus 
PRRSV isolate 12-39404A was recovered from serum collected from five-week-
old nursery pigs located in Northwest Iowa in 2012. PRRSV 12-39404A was amplified 
by three passages on MARC-145 cells as previously described.
25
 Infected cells were 
lysed by two freeze-thaw cycles after a PRRSV-specific cytopathic effect was observed. 
Clarification by centrifugation at 2000 x g for 10 min to pellet cell debris was followed 
by titration on MARC-145 cells, distribution of the virus in 5 ml aliquots and freezing at -
80°C until challenge. 
 
Experimental design 
Pigs were block randomized by weight into three groups: non-vaccinated/non-
challenged (NV/NC; n=21), non-vaccinated/challenged (NV/C; n=21), and 
vaccinated/challenged (V/C; n=20). Groups were housed in the same facility, but 
separated by room and ventilation system. Pigs in each room were fed a balanced diet ad 
libitum based on weight and given free access to water. At 0 days post vaccination (dpv) 
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pigs in the V/C group received a 2 ml intramuscular (IM) dose of Fostera™ PRRS 
vaccine per manufacturer’s instructions. Pigs in the NV/NC and NV/C groups received a 
2 ml IM dose of sterile diluent. At 28 dpv (0 days post inoculation (dpi)), pigs in the 
NV/C and V/C groups received 2 ml IM and 2 ml intranasal (IN) doses of challenge virus 
at 1x10
5
 TCID50/ml. The NV/NC group received 2 ml IM and 2 ml IN doses of sterile 
cell culture medium. Serum was collected on 0, 14, and 28 dpv, and 3, 7, and 12 dpi. Pen-
based oral fluids were collected on 0, 7, 14, 21, and 28 dpv, and 3, 7, and 12 dpi. Humane 
euthanasia was performed with a lethal dose of pentobarbital (Fatal-Plus, Vortech 
Pharmaceuticals, Ltd. Dearborn, MI) at 12 dpi. Fresh and formalin fixed samples 
collected at necropsy included: lung, tonsil, tracheobronchial, mediastinal, iliac, and 
inguinal lymph nodes. Five sections of formalin fixed lung were collected from the right 
cranial, right caudal, and the accessory lung lobes of each pig after insufflation and 
submersion for 15 minutes in 10% neutral buffered formalin. Broncho-alveolar lavage 
fluid (BALF) was collected from the left lung lobes at necropsy. The experimental design 
is described in Table 1 and was approved by the Iowa State University Institutional 
Animal Care and Use Committee (protocol log #10-13-7659-S). 
 
Clinical assessment 
Body weights were recorded for each pig on arrival, prior to challenge (25 dpv), 
and at necropsy (12 dpi). Weights were used for calculating average daily gain (ADG). 
Rectal temperature was recorded from -1 dpi through 7 dpi, and again at 10 dpi.  
 
 
43 
 
  
Pathology 
At necropsy, lungs were evaluated for the presence of macroscopic lesions typical 
of PRRSV by a single veterinary pathologist blinded to the treatment groups. The percent 
of the lung surface affected with pneumonia was subjectively estimated for each lung 
lobe and the total percentage affected was calculated based on weighted proportions of 
each lobe relative to the total lung volume as previously described.
26
 After 48 hrs fixation 
in neutral buffered formalin, tissue sections were trimmed, processed, and embedded in 
paraffin. Four micron thick sections were cut and stained with hematoxylin and eosin. All 
five lung sections were scored individually for interstitial pneumonia by a single 
veterinary pathologist blinded to the study, using the following scale: 0=normal, 1=mild 
multifocal, 2=mild diffuse, 3=moderate multifocal, 4=moderate diffuse, 5=severe 
multifocal, 6=severe diffuse. The scores were averaged to obtain an overall microscopic 
lung lesion score for each pig. 
 
Differential Quantitative PCR 
All PCR assays were conducted at the Iowa State University Veterinary 
Diagnostic Laboratory (ISU-VDL). Serum and oral fluid samples collected prior to 
challenge were extracted using the MagMAX™ Viral RNA Isolation Kit (Life 
Technologies, Carlsbad, CA) and a Kingfisher 96 instrument (Thermo Scientific, 
Waltham, MA) according to manufacturer’s instructions. Real-time RT-PCR was 
performed on nucleic acid extracts using the commercially available MagMAX™ NA 
and EU PRRSV-specific PCR assay (Life Technologies Carlsbad, CA) to detect the 
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presence of Fostera™ PRRSV vaccine virus and ensure non-vaccinated pigs were virus 
negative. 
Post-challenge serum, oral fluids, BALF, lung and tonsil were analyzed by a 
multiplex real-time RT-PCR with primers and probes designed at the ISU-VDL 
specifically targeting the challenge or vaccine virus. Three grams of fresh lung and tonsil 
were placed in 30 ml of MEM, processed by a tissue stomacher, and centrifuged to make 
a 10% homogenate. Samples were extracted using the MagMAX™ Viral RNA Isolation 
Kit (Life Technologies, Carlsbad, CA) and a Kingfisher 96 instrument (Thermo 
Scientific, Waltham, MA) according to manufacturer’s instructions. Real-time RT-PCR 
was performed on nucleic acid extracts using the commercially available MagMAX™ 
NA and EU PRRSV-specific PCR assay (Life Technologies Carlsbad, CA) and 
substituting 400 nM of each forward and reverse primer and 200 nM of the probe specific 
to the challenge or vaccine virus (Table 2). Serum, lung and BALF reactions included 
12.5 μl of 2X RT-PCR buffer, 2.5 μl of 10X PRRSV primer probe mix, 1.25 μL of 20X 
multiplex RT-PCR enzyme mix, and 0.75 μl of nuclease-free water. Each oral fluid 
reaction used the same volume of reagents described for the serum with the exception of 
2.5 μL of 20X multiplex RT-PCR enzyme mix and 0.5 μL of nuclease-free water. A final 
volume of 25 μL consisting of 17 μL mastermix and 8 μL of RNA extract for the serum, 
lung and BALF samples or 18 μL mastermix and 7 μL of RNA extract for the oral fluid 
samples was placed in each well of a 96-well fast PCR plate (Life Technologies 
Carlsbad, CA). Real-time RT-PCR was performed using an AB 7500 fast thermocycler 
with the following cycling conditions: 1 cycle at 45°C for 10 min, 1 cycle at 95°C for 10 
min, and 40 cycles of 97°C for 2 sec, 60°C for 40 sec. Amplification curves were 
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analyzed with commercial thermal cycler system software. Each PCR assay included 
eight progressive 1:10 dilutions of a known copy number of 12-39404A and Fostera™ 
PRRS vaccine virus based on genomic copies per ml. Aliquots of each dilution were 
stored at -80°C and used as the standard curve for quantitative RT-PCR. 
 
Serology 
All serology assays were conducted at the Iowa State University Veterinary 
Diagnostic Laboratory (ISU-VDL) according to laboratory procedures. Serum from 
individual pigs and oral fluid samples from each pen post-vaccination and post-challenge 
were analyzed for the presence of anti-PRRSV antibody using the PRRSV X3 ELISA 
(IDEXX, Westbrook, ME). 
 
Statistical Analysis 
Percent pneumonia, lung lesion histopathology scores, log10 transformed PRRSV 
genomic copies in serum, lung, tonsil and BALF and PRRSV ELISA S/P ratios were 
analyzed using the Wilcoxon rank-sum test with a P-value ≤ 0.05 considered significant 
(SAS, SAS Institute, Cary, NC). Response variables shown to have a significant effect by 
treatment group were subjected to pair-wise comparisons using the Kruskal-Wallis test. 
Weight data was analyzed using analysis of variance (ANOVA). Response variables 
shown to have a significant effect by treatment group were subjected to pair-wise 
comparisons using the Tukey–Kramer test. A P-value ≤ 0.05 was considered significant. 
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Results 
Pre- and post-screening Microbiological Assays 
No extraneous viral or bacterial nucleic acid was detected in serum (PRRSV, 
PCV2) or nasal swabs (IAV, MHP) from pigs prior to the start of the experiment. All pigs 
were free of anti-PRRSV and -MHP antibodies prior to the start of the study. One of 62 
pigs was positive for influenza A nucleoprotein antibody, and 27/62 pigs were positive 
for anti-PCV2 antibodies prior to the start of the experiment. BALF collected from all 
pigs at necropsy (12 dpi) tested negative for PCV2, IAV, and MHP nucleic acid.  
 
Pre-challenge PRRSV ELISA and RT-PCR 
All pigs in the V/C group were PRRSV ELISA antibody positive on 14 and 28 
dpv with S/P ratios of 0.95 and 1.58, respectively (Figure 1). Fostera™ PRRS vaccine 
virus was detected in serum by PCR in 95% (19/20) and 85% (17/20) of pigs at 14 and 28 
dpv, respectively. Pen-based oral fluid samples collected from the V/C group were 
positive for PRRSV ELISA antibody and Fostera™ PRRS vaccine virus at 7, 14, 21 and 
28 dpv (data not shown). All pigs in the NV/NC and NV/C groups were PRRSV PCR 
and PRRSV antibody negative in serum and oral fluids during the pre-challenge phase of 
the study. 
 
Clinical Disease 
Pigs in the NV/NC group did not exhibit respiratory clinical signs for the duration 
of the study. Clinical signs of respiratory disease were not observed in the NV/C or V/C 
groups from 0 to 28 dpv. Pigs in the NV/C group became depressed, lethargic, and mildly 
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anorexic at 5 dpi, with a majority of pigs more severely affected at 7 dpi and clinical 
signs persisting through 12 dpi. The V/C group demonstrated mild lethargy from 7-10 
dpi, although anorexia was not clinically apparent. Significant trends were not observed 
between the V/C and NV/C group mean body temperatures at any time point during the 
study (data not shown). 
 
Lung Pathology 
Macroscopic lesions in the NV/C and V/C group were characterized by mild to 
moderate enlargement of tracheobronchiolar lymph nodes and varying amounts of lung 
surface affected by mottled-tan pneumonia that were more extensive in the NV/C pigs 
(Figure 2). Mean percent pneumonia was significantly lower in the V/C group (mean 
10.2%; range 0-40%) compared to the NV/C group (mean 16.9%; range 5-51%) at 
necropsy (Table 3). The NV/NC group averaged 2.0% pneumonia (range 0-13%). 
Microscopic lesions consisted of multifocal to diffuse, mild to severe lymphohistiocytic 
interstitial pneumonia (Figure 2). Microscopic interstitial pneumonia scores were 
significantly lower in the V/C group (mean 2.41; range 1.0-4.2) compared to the NV/C 
group (mean 3.13; range 1.4-5.4) (Table 3). The NV/NC group mean score was 1.57 
(range 0.2-2.8). 
 
Post-challenge PRRSV Quantitative RT-PCR 
PRRSV virus was not detected by RT-PCR in the NV/NC group at any time 
during the study. Fostera™ PRRS virus was not detected by the differential, multiplex 
RT-PCR in the NV/C or V/C groups throughout the post-challenge period. Challenge 
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virus was detected in serum from all pigs in the NV/C and V/C groups at 3, 7 and 12 dpi 
(Table 4). Mean PRRSV log10 genomic copies/ml of serum from NV/C and V/C pigs was 
not statistically different at 3 dpi. At 7 and 12 dpi, mean PRRSV log10 genomic copies/ml 
were significantly lower in the V/C group compared to the NV/C pigs.  
Oral fluid samples from NV/C and V/C groups were positive for challenge virus 
at 3, 7, and 12 dpi (Table 4). Mean PRRSV log10 genomic copies/ml of oral fluid from 
NV/C and V/C pigs were similar at 3 dpi, and demonstrated a lower trend in the V/C 
group at 7 and 12 dpi.  
PRRSV was not detected in tissues from the NV/NC group at necropsy. Mean 
log10 genomic copies/ml of the challenge virus in lung homogenate and BALF were 
significantly lower in the V/C pigs compared to the NV/C group (Table 3). In contrast, 
the NV/C group had significantly lower amounts of challenge virus in tonsil homogenate 
compared to the V/C group (Table 3).  
 
Post-Challenge PRRSV ELISA Antibody 
All pigs in the V/C group were positive for PRRSV ELISA antibody in serum at 
3, 7, and 12 dpi with mean S/P ratios of 1.82, 2.05, and 2.20, respectively. PRRSV 
ELISA antibody was also detected in pen-based oral fluid samples at 3, 7 and 12 dpi in 
the V/C group (data not shown). Post-challenge, 0/21, 18/21, and 21/21 pigs in the NV/C 
group were PRRSV ELISA antibody positive via serum at 3, 7, and 12 dpi, respectively 
(Figure 1). The NV/C group was PRRSV antibody negative via oral fluid at 3 dpi, and 
PRRSV ELISA antibody positive at 7 and 12 dpi (data not shown). All pigs in the 
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NV/NC group were PRRSV antibody negative via serum and oral fluids throughout the 
challenge period. 
 
Production Parameters 
A statistical difference was not observed in mean average daily gain (ADG) between 
NV/NC, NV/C and V/C pigs from vaccination until challenge. Post-challenge mean ADG 
was significantly higher in the V/C group (0.71 kg/day) compared to the NV/C group 
(0.58 kg/day) (Table 5). The post-challenge NV/C and V/C mean ADG was significantly 
lower compared to the NV/NC group (0.84 kg/day).  
 
Discussion 
Porcine reproductive and respiratory syndrome virus has spread globally since its 
emergence in the US and is the most economically significant pathogen affecting the 
swine industry worldwide.
4,27
 Swine producers have implemented multiple programs to 
prevent the introduction of PRRSV into negative herds or eliminate entry of a variant 
virus into infected but PRRSV stable farms.
28,29
 One of the primary objectives of an 
effective PRRSV control program at the herd level is to produce PRRSV negative piglets 
at weaning.
30
 Procedures commonly used to achieve this outcome include gilt 
acclimation,
30
 live virus inoculation or exposure,
31
 and implementation of inactivated or 
modified live virus vaccines. Currently, MLV PRRSV vaccines have demonstrated more 
consistent efficacy compared to inactivated products and provide adequate protection 
against reinfection with homologous PRRSV
24,32
 or reduce viral shedding.
33
 However, 
protection against challenge with a heterologous PRRSV may vary or be 
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incomplete.
17,18,19,23,34,35,36
 In addition, experimental studies often use historic PRRSV 
isolates for challenge, such as VR-2332, that may not represent the diverse ecology of 
PRRSV currently circulating in swine.
18,32,33
 
 The objective of the current study was to evaluate the efficacy of Fostera™ 
PRRS, a commercial MLV vaccine, against a heterologous lineage 9 virus considered 
representative of contemporary PRRSV circulating in swine. A phylogenetic analysis 
based on the ORF5 and using lineage reference strains identified several recent lineage 9 
isolates at the ISU VDL.
37
 Isolate 12-39404 was chosen as the challenge virus after a 
pilot study in weaned pigs confirmed it was a virulent strain that induced macroscopic 
and microscopic lung lesions (data not shown). The 12-39404 challenge virus RFLP is 1-
4-2 and the ORF5 nucleotide homology is 92.5% with Fostera™ PRRS and 91.5% 
homologous to the lineage 9 reference strain NADC20 (Figure 3). Whole genome 
sequencing determined 12-39404 is 92.6% and 82.6% homologous to the Fostera™ 
PRRS whole genome nucleotide and amino acid sequences, respectively. The challenge 
virus was considered sufficiently heterologous to the Fostera™ PRRS, which is based on 
the virulent lineage 8 US PRRSV isolate P129.  
 Fostera™ PRRS conferred partial cross-protection against clinical disease and 
infection in V/C pigs compared to the NV/C group that overall demonstrated more severe 
clinical signs although mortality was not observed in either challenge group. Mean 
percent pneumonia was 39.6% lower in the V/C group compared to the NV/C pigs 
(10.2% vs. 16.9%, respectively) and microscopic lesion scores were significantly lower 
in pigs that received Fostera™ PRRS vaccine. Challenge virus was detected at 
significantly lower levels in the lung and BALF from vaccinated pigs suggesting a 
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reduction in viral replication may have been responsible for the decreased severity of 
lung lesions compared to the NV/C group at necropsy. However, it is unknown why this 
trend was reversed in the tonsil where the quantity of challenge virus was higher in V/C 
pigs compared to the non-vaccinated group. The tonsil consists of lymphoid and 
connective tissue that may be more difficult to uniformly homogenize compared to the 
lung suggesting disproportionate quantities of the tissue may have falsely lowered the 
level of challenge virus detected in some of the NV/C pigs. PRRSV persists longer in 
tonsil and lymph nodes than serum and lung, up to 157 days under experimental 
conditions.
38,39
 Challenged pigs in the current study were euthanized at 12 dpi to 
maximize the severity of lung lesions, which may have limited the time available to allow 
differences in PRRSV replication between the V/C and NV/C tonsil to be detected. These 
data are consistent with previous reports that describe tonsil as a source of virus during 
persistent infection.
40,41,42
 However, even in the presence of humoral immunity, PRRSV 
asymptomatic infections have been shown to persist in tonsil and other lymphoid tissues, 
which may suggest a reason for the lack of differences in virus quantities observed in the 
tonsil from V/C and NV/C pigs in the current study.
38
 
Although similar levels of 12-39404 were detected via qRT-PCR at 3 dpi in both 
challenge groups, PRRSV viremia was significantly reduced at 7 and 12 dpi in the V/C 
pigs. Pen-based oral fluid samples collected at 7 and 12 dpi also demonstrated lower 
levels of challenge virus in pigs that received MLV vaccine. These data suggest 
Fostera™ PRRSV vaccine reduced viremia in spite of the heterogeneity between vaccine 
and challenge viruses. In contrast, previous PRRSV MLV vaccine and challenge studies 
did not demonstrate significant reductions in viremia.
22,35,43
 The reason for the discrepant 
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results with the current study remains unknown although the previous studies were 
conducted in naturally infected pigs where level of virus exposure may have varied 
among challenged pigs and genetic or antigenic differences between vaccine and 
challenge viruses may have varied between studies. PRRSV ELISA antibody was 
detected in Fostera™ PRRS vaccinated pigs at the time of challenge suggesting the 
immune response elicited by the vaccine contributed to a reduction in viremia. 
Interestingly, PRRSV fluorescent focus neutralizing (FFN) assays with Fostera™ PRRS 
antisera from pigs vaccinated longer than 42 dpi were conducted against the challenge 
virus and determined negative (data not shown) indicating a neutralizing antibody 
response specific to the 12-39404 PRRSV was not induced by Fostera™ PRRS or present 
at the time of challenge. It is unknown which component of the immune response may 
have contributed to partial protection or if biological factors contributed to the difference 
in level of viremia. The properties that induce protection after infection with live virus 
have not been fully elucidated.
15
 However, differences in level of viremia observed 
between the Fostera™ PRRSV vaccinated and non-vaccinated pigs suggests the immune 
response, humoral or cell-mediated, may have contributed to the partial-protection 
observed in the current study. 
Economic losses due to PRRSV infections in nursery and grow-finish swine are 
attributed to poor production realized through decreased average daily gain, reduced feed 
efficiency and increased mortality.
4
 Mortality was not observed in the current study; 
however, pigs euthanized at 12 dpi may have precluded the time necessary to experience 
death loss under the conditions of the study. In contrast, 12 dpi was sufficient to detect 
significant differences in average daily gain (ADG) among the negative control and two 
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challenge groups. Although vaccinated pigs demonstrated lower ADG from vaccination 
until challenge compared to the non-challenged pigs, differences were not significant. 
Post-challenge, V/C pigs gained 18.3% more body weight per day compared to the NV/C 
group. A previous study demonstrated similar production advantages in vaccinated pigs 
after heterologous challenge compared to the non-vaccinated, challenged pigs in spite of 
similar levels of viremia between the experimental groups.
36
 The significantly elevated 
ADG recorded in the NV/NC pigs compared to the groups that received 12-39404 
supports the pathogenicity of the challenge virus. However, the lower levels of virus 
detected in the lung and reduced viremia detected in Fostera™ PRRS vaccinated pigs 
may have improved pig performance compared to non-vaccinated pigs in spite of partial 
cross-protection. At necropsy, clinical signs (depression and lethargy) in the V/C group 
were resolving while the NV/C group appeared to be at peak severity. It is unknown if 
extending the length of the challenge period would have resulted in even greater disparity 
in ADG between the V/C and NV/C groups. 
In summary, vaccination with Fostera™ PRRS resulted in partial cross-protection 
against a contemporary, heterologous lineage 9 PRRSV isolated from a recent infection 
in nursery pigs. While cross-protection was not complete, vaccination corresponded with 
decreased levels of 12-39404 in serum and virus replication in lung and BALF, reduced 
gross and microscopic lung lesions and increased ADG compared to challenged pigs that 
did not receive vaccination. Future studies are needed to evaluate cross-protection against 
PRRSV from different lineages that demonstrate greater heterogeneity or antigenic 
variation than what has been described in the current study, using contemporary viruses 
that represent potential field infections. Lengthening the challenge period to gain further 
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insight into the production benefits of Fostera™ PRRS vaccination may provide 
additional useful information. Prevention and control of PRRSV continues to challenge 
the swine industry and additional challenge studies using commercially available 
vaccines and contemporary isolates are necessary. 
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Table 1. Experimental design 
      Days post vaccination: dpv  Days post inoculation: dpi 
Group N Age Vaccine Age Challenge 0 7 14 21  0 3 7 12 
NV/NC 21 4 wks Non-vaccinated 8 wks Non-challenged S, NS, OF OF S, OF OF  S, OF S, OF S, OF 
S, OF 
Necropsy 
NV/C 21 4 wks Non-vaccinated 8 wks ISU-12-39404 S, NS, OF OF S, OF OF  S, OF S, OF S, OF 
S, OF 
Necropsy 
V/C 20 4 wks Fostera PRRSV 8 wks ISU-12-39404 S, NS, OF OF S, OF OF  S, OF S, OF S, OF 
S, OF 
Necropsy 
NV/NC: non-vaccinated/non-challenged; NV/C: non-vaccinated/challenged; V/C: vaccinated/ challenged; S: serum; NS: nasal swab;  
OF: oral fluid; BALF: bronchoalveolar lavage fluid 
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Table 2. Nucleotide sequences of the forward and reverse primers and individual probes for 12-39404A challenge PRRSV and 
Fostera™ PRRS vaccine viruses used in the real time RT-PCR for absolute quantification of PRRSV genomic copies. 
Name Sequence 
PRRSV (forward primer) 5’-GTGCTCTGGCTGCGTTGA-3’ 
PRRSV (reverse primer) 5’-CGCCAGGACATGCAGTTCT-3’ 
12-39404A PRRSV (MGB probe) 5’-VIC-TTGCTTCATCATCAGGTTT-3’ 
Fostera™ PRRS Vaccine (MGB probe) 5’-FAM-TTGCTTCGTTATTAGGCTTG-3’ 
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Table 3. Mean macroscopic pneumonia, microscopic lung lesion scores and quantitative RT-PCR values for challenge virus in lung, 
BALF and tonsil collected from NV/NC, NV/C and V/C pigs at 12 dpi ± standard error of the mean. Different letters within a column 
represent a statistical difference at P< 0.05. 
Group 
Lung Lesions  Quantitative PCR (Mean log 10 genomic copies/ml±SE) 
Macroscopic 
percent pneumonia 
(Mean±SE) 
Microscopic lung 
scores 
(Mean±SE) 
 
Lung BALF Tonsil 
NV/NC 2.0 ± 0.1
a
 1.57 ± 0.20
a
  0.00 ± 0.00
a
 0.00 ± 0.00
a
 0.00 ± 0.00
a
 
NV/C 16.9  ± 2.3
b
 3.13 ± 0.24
b
  6.93  ± 0.08
b
 7.23 ± 0.09
b
 6.71 ± 0.08
b
 
V/C 10.2 ± 2.4
c
 2.41 ± 0.20
c
  5.71 ± 0.19
b
 6.56 ± 0.19
c
 7.04 ± 0.09
c
 
NV/NC, non-vaccinated-non-challenged; NV/C, Non-vaccinated-challenged; V/C, vaccinated-challenged 
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Table 4. Mean PRRSV 12-39404A log10 genomic copies/ml ± standard error of the mean for serum and pen-based oral fluid samples from 
NV/NC, NV/C and V/C pigs collected at 0, 3, 7 and 12 days post-inoculation (dpi). Different letters within a column are statistically 
different at P< 0.05. 
 
Serum (Mean log 10 genomic copies/ml±SE)  Oral Fluid (Mean log 10 genomic copies/ml±SE) 
Group 3 dpi 7 dpi 12 dpi  3 dpi 7 dpi 12 dpi 
NV/NC 0.00 ± 0.00
a
 0.00 ± 0.00
a
 0.00 ± 0.00
a
  0.00  0.00  0.00  
NV/C 6.30  ± 0.12
b
 6.93 ± 0.09
b
 6.19 ± 0.15
b
  4.91   5.23  4.95  
V/C 6.10 ± 0.14
b
 5.61 ± 0.19
c
 3.87 ± 0.26
c
  5.08  4.69  3.14  
NV/NC, non-vaccinated-non-challenged; NV/C, Non-vaccinated-challenged; V/C, vaccinated-challenged 
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Table 5. Average daily gain reported in kilograms during the post-vaccination and post-challenge 
phase of the study in NV/NC, NV/C and V/C groups ± standard error of the mean. Different 
letters within a column are statistically different at P < 0.05. 
  Average Daily Gain in Kilograms 
Group  Post-Vaccination 
(-3 to 25dpv)  
Post-Challenge 
(25dpv to 12dpi) 
NV/NC  0.49 ± 0.02
a
  0.84 ± 0.02
a 
NV/C  0.50 ± 0.01
a  0.58 ± 0.03b 
V/C  0.46 ± 0.02
a  0.71 ± 0.03c 
NV/NC, non-vaccinated-non-challenged; NV/C, Non-vaccinated-challenged; V/C, vaccinated-
challenged 
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Figure 1. Mean anti-PRRSV ELISA antibody S/P ratios in serum from NV/NC, NV/C and V/C 
pigs at 0, 14 and 28 days post vaccination (dpv) and 3, 7 and 12 days post inoculation (dpi). Error 
bars represent standard error of the mean. 
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Figure 2. Macroscopic and microscopic lung lesions observed at necropsy in (A) NV/NC, (B) 
NV/C and (B) V/C pigs challenged with placebo or 12-39404 PRRSV. 
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Figure 3. Phylogenetic analysis showing lineage classification and diversity, based on ORF 5 
sequences, between historical reference PRRSV strains, several PRRSV strains used in vaccines, 
Fostera™ PRRS vaccine strain, and the PRRSV strain (12-39404) selected for challenge. 
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Abstract 
Porcine reproductive and respiratory syndrome virus is a diverse, ever-changing 
RNA virus that causes severe economic loss to the swine industry. Vaccination of pigs 
with modified live PRRSV vaccines have been used to control the impact of strains 
circulating within a herd, but have demonstrated variable protection against the 
introduction of antigenically diverse PRRSV. The objective of this study was to evaluate 
the efficacy of a commercial MLV PRRSV vaccine, Fostera™ PRRS, against challenge 
with a contemporary, heterologous lineage 1 virus. The challenge virus was isolated from 
serum collected from nursery pigs in Iowa in 2014, and shared 84.4% ORF5 nucleotide 
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homology with the vaccine strain. Viremia was significantly lower in vaccinated and 
challenged pigs at 3, 7, and 12 dpi, and average daily gain during the post-challenge 
period was significantly higher compared to the non-vaccinated and challenged pigs. 
Significantly lower levels of challenge virus were detected in bronchoalveolar lavage 
fluid from vaccinated pigs at necropsy. However, gross and microscopic lung lesion 
scores between vaccinated and non-vaccinated pigs were not significantly different. 
These data suggest that vaccination with Fostera™ PRRS elicited partial protection 
against a recently isolated, heterologous PRRSV lineage 1 virus demonstrated by the 
improved average daily gain and reduction in viremia in growing pigs challenged 28 days 
after vaccination. 
 
Introduction 
Porcine reproductive and respiratory syndrome virus (PRRSV) is an enveloped, 
single-stranded RNA virus belonging to the Order Nidovirales and the family 
Arteriviridae.
1
 Clinical disease results in reproductive failure and abortion in sows and 
respiratory disease in growing pigs; the clinical disease is commonly referred to as 
porcine reproductive and respiratory syndrome (PRRS). The classic pathologic lesion 
caused by viral infection in growing pigs is interstitial pneumonia; however, studies have 
shown that PRRSV infection can also result in increased susceptibility to co-infections 
with other viral and bacterial pathogens.
2
 Recently, PRRSV was estimated to cost the 
United States (US) swine industry approximately $664 million each year, currently 
making PRRS  the most economically important disease to the US swine industry.
3
 The 
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economic effects of viral infection in growing pigs are the result of decreased feed 
efficiency and increased mortality.
3
  
There are two recognized genotypes of PRRSV; European type 1 (reference strain 
Lelystad) and North American type 2 (reference strain VR-2332) and viruses in both 
genotypes display considerable genetic diversity. Type 2 PRRSV strains have been 
further classified into nine separate lineages based on phylogenetic analysis.
4
 This 
classification system groups genetically similar PRRSV together, and as a result, the open 
reading frame 5 (ORF5) sequences within each virus lineage demonstrate no more than 
11% nucleotide diverstiy.
4
 The vast majority of PRRSV sequences fall into only 4 
lineages (1, 5, 8 and 9). Classification of PRRSV strains is a helpful tool in 
epidemiological studies and may aid attempts to control disease, due to their high degree 
of genetic and antigenic diversity and the lack of cross-protection between strains elicited 
after natural infection. High rates of genetic mutation and recombination continue to 
allow PRRSV to evolve rapidly, and pose a challenge to the development of cross-
protective vaccines.
4,5,6,7
 
 Both inactivated and modified live virus (MLV) PRRSV vaccines have been 
developed with the intent to stimulate broad cross-protection. Inactivated vaccines have 
been shown to be ineffective when used alone, but may potentially induce an anamnestic 
response after previous vaccination or natural infection. Modified live virus PRRS 
vaccines have been proven more efficacious at eliciting an immune response, and have 
demonstrated adequate protection against homologous challenge. Studies evaluating 
PRRSV MLV vaccines against heterologous challenge have found varying levels of 
partial protection based on a reduction in clinical signs and/or pathologic lung 
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lesions.
8,9,10,11,12
 A recent field trial reported Fostera™ PRRS vaccination improved 
weight gain and decreased mortality and gross lung lesions; however, the trial did not use 
a heterologous virus or a standardized challenge dose of virus, and vaccinated pigs did 
not show differences in magnitude of viremia.
13
 
While there are no commercial vaccines currently available that are based on a 
lineage 1 PRRSV, this genetic lineage encompasses the second highest number of virus 
strains with a published sequence.
4
 Lineage 1 includes MN184 as the prototype virus and 
its variants characterized by various nucleotide deletions in the genome. The prototype 
virus was associated with a severe outbreak of PRRSV in the early 2000’s.14 Due to the 
prevalence of lineage 1 viruses and their potential for causing severe respiratory disease 
and abortion, vaccine induced cross-protection against this lineage is an important 
component of disease control and potential elimination in a single herd or in regional 
control efforts.  
The objective of this study was to assess the efficacy of Fostera™ PRRS vaccine 
in growing pigs compared to non-vaccinated pigs after challenge with a lineage 1 PRRSV 
isolated in 2014. Viremia, gross and microscopic lung lesions, virus levels in lung, 
bronchoalveolar lavage fluid (BALF) and tonsil as well as average daily gain were 
evaluated.  
 
Materials and Methods 
Animals 
Fifty-six, four-week-old male weaned pigs were sourced from a single 
commercial, cross-bred farrow-to-wean herd. Upon arrival, all pigs were tested via PCR 
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for PRRSV and porcine circovirus type 2 (PCV2) in serum and influenza A virus (IAV) 
and Mycoplasma hyopneumoniae (MHP) in nasal swabs.  Pigs were tested at the Iowa 
State Univeristy Veterinary Diagnostic Laboratory for the presence of antibody to 
PRRSV, IAV, PCV2, and MHP in serum prior to the start of the trial and pigs were 
administered no vaccines prior to arrival. All pigs were administered an intramuscular 
(IM) injection of ceftiofur crystalline free acid (Excede®, Zoetis, Florham Park, NJ) per 
label instructions upon arrival to the research facility and one day prior to challenge, and 
one IM injection of enrofloxacin (Baytril®, Bayer Healthcare, LLC, Shawnee Mission, 
KS) one day prior to vaccination to control potential secondary bacterial infections.   
 
PRRSV challenge virus 
PRRSV isolate 14-4099 was recovered from serum collected from five-week-old 
nursery pigs located in Northwest Iowa in 2014 with clinical signs that included 
coughing, malaise and respiratory distress. PRRSV 14-4099 was amplified by three 
passages on MARC-145 cells as previously described.
15
 Infected cells were lysed by two 
freeze-thaw cycles after a PRRSV-specific cytopathic effect was observed. Clarification 
by centrifugation at 2000 x g for 10 min to pellet cell debris was followed by titration on 
MARC-145 cells, distribution of the virus in 5 ml aliquots and freezing at -80°C until 
challenge. 
 
Experimental design 
Pigs were block randomized by weight into three groups: non-vaccinated/non-
challenge (NV/NC; n=9), non-vaccinated/challenged (NV/C; n=24), and 
vaccinated/challenged (V/C; n=23). Groups were housed in the same facility, but 
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separated by room and ventilation system prior to challenge. Each group was divided into 
pens of two pigs, with two pens containing only one pig. Pigs in each room were fed a 
balanced diet ad libitum based on weight and given free access to water. At 0 days post 
vaccination (dpv) pigs in the V/C group received a 2 ml intramuscular (IM) dose of 
Fostera™ PRRS vaccine per manufacturer’s instructions. Pigs in the NV/NC and NV/C 
groups received a 2 ml IM dose of sterile diluent. At 28 dpv (0 days post inoculation 
(dpi)) pigs in the NV/C and V/C groups received 2 ml IM and 2 ml intranasal (IN) doses 
of challenge virus at 1x10
5
 TCID50/ml. The NV/NC group received 2 ml IM and 2 ml IN 
doses of sterile cell culture medium. In addition, pigs were co-mingled at challenge by 
randomly selecting one-half of the pigs in the NV/C and V/C groups, respectively, and 
moving them into the corresponding pens in the opposite rooms. Serum was collected 
from individual pigs at 0, 14, and 28 dpv, and 3, 7, and 12 dpi. Oral fluid samples were 
collected from each pen at 0, 7, 14, 21, and 28 dpv, and 3, 7, and 12 dpi. Humane 
euthanasia was performed with a lethal dose of pentobarbital (Fatal-Plus, Vortech 
Pharmaceuticals, Ltd. Dearborn, MI) at necropsy (12 dpi). Fresh and formalin fixed tissue 
samples collected at necropsy included: lung, tonsil, tracheobronchial, mediastinal, iliac, 
and inguinal lymph nodes. Five sections of formalin fixed lung were collected from the 
right cranial, right caudal, and accessory lung lobes of each pig after insufflation with and 
submersion in 10% neutral buffered formalin for 15 minutes for further fixation. 
Broncho-alveolar lavage fluid was collected from the left lung lobes at necropsy. The 
experimental design is described in Table 1 and was approved by the Iowa State 
University Institutional Animal Care and Use Committee (protocol log #10-13-7659-S). 
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Clinical assessment 
Body weights were recorded for each pig on arrival, prior to challenge (26 dpv), 
and at necropsy (12 dpi). Weights were used for calculating average daily gain (ADG). 
Rectal temperature was recorded from -1 dpi through 7 dpi, and at 10 dpi. 
 
Pathology 
At necropsy, lungs were evaluated for the presence of macroscopic lesions typical 
of PRRSV by a single veterinary pathologist blinded to the treatment groups. The percent 
of the lung surface affected with pneumonia was subjectively estimated for each lung 
lobe and the total percentage affected was calculated based on weighted proportions of 
each lobe relative to the total lung volume as previously described.
16
 After 48 hrs of 
fixation in neutral buffered formalin, tissue sections were trimmed, processed, and 
embedded in paraffin. Four micron thick sections were cut and stained with hematoxylin 
and eosin. All five lung sections were scored individually for interstitial pneumonia by a 
single veterinary pathologist blinded to the study, using the following scale: 0=normal, 
1=mild multifocal, 2=mild diffuse, 3=moderate multifocal, 4=moderate diffuse, 5=severe 
multifocal, 6=severe diffuse. The scores designated for each section were averaged to 
obtain an overall microscopic lung lesion score for each pig. 
 
Post-Challenge Quantitative PCR 
All PCR assays were conducted at the Iowa State University Veterinary 
Diagnostic Laboratory (ISU-VDL). Serum and oral fluid samples collected prior to 
challenge were extracted using the MagMAX™ Viral RNA Isolation Kit (Life 
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Technologies, Carlsbad, CA) and a Kingfisher 96 instrument (Thermo Scientific, 
Waltham, MA) according to manufacturer’s instructions. Real-time RT-PCR was 
performed on nucleic acid extracts using the commercially available MagMAX™ NA 
and EU PRRSV-specific PCR assay (Life Technologies Carlsbad, CA) to detect the 
presence of Fostera™ PRRSV vaccine virus and ensure non-vaccinated pigs were virus 
negative. 
Post-challenge serum, oral fluids, BALF, lung and tonsil were analyzed by a real-
time RT-PCR with primers and probes designed at the ISU-VDL specifically targeting 
ORF5 of the challenge virus. Three grams of fresh lung and tonsil were placed in 30 ml 
of MEM, processed by a tissue stomacher, and centrifuged to make a 10% homogenate. 
Samples were extracted using the MagMAX™ Viral RNA Isolation Kit (Life 
Technologies, Carlsbad, CA) and a Kingfisher 96 instrument (Thermo Scientific, 
Waltham, MA) according to manufacturer’s instructions. Real-time RT-PCR was 
performed on nucleic acid extracts using the commercially available MagMAX™ NA 
and EU PRRSV-specific PCR assay (Life Technologies Carlsbad, CA) and substituting 
400 nM of each forward and reverse primer and 200 nM of the probe specific to the 
challenge virus (Table 2). Serum, lung and BALF reactions included 12.5 μl of 2X RT-
PCR buffer, 2.5 μl of 10X PRRSV primer probe mix, 1.25 μL of 20X multiplex RT-PCR 
enzyme mix, and 0.75 μl of nuclease-free water. Each oral fluid reaction used the same 
volume of reagents described for the serum with the exception of 2.5 μL of 20X 
multiplex RT-PCR enzyme mix and 0.5 μL of nuclease-free water. A final volume of 25 
μL consisting of 17 μL mastermix and 8 μL of RNA extract for the serum, lung and 
BALF samples or 18 μL mastermix and 7 μL of RNA extract for the oral fluid samples 
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was placed in each well of a 96-well fast PCR plate (Life Technologies Carlsbad, CA). 
Real-time RT-PCR was performed using an AB 7500 fast thermocycler with the 
following cycling conditions: 1 cycle at 45°C for 10 min, 1 cycle at 95°C for 10 min, and 
40 cycles of 97°C for 2 sec, 60°C for 40 sec. Amplification curves were analyzed with 
commercial thermal cycler system software. Each PCR assay included eight progressive 
1:10 dilutions of a known copy number of 14-4099 challenge virus based on genomic 
copies per ml. Aliquots of each dilution were stored at -80°C and used as the standard 
curve for quantitative RT-PCR. 
 
Serology 
All antibody assays were conducted at the Iowa State University Veterinary 
Diagnostic Laboratory (ISU-VDL) according to laboratory procedures. Serum from 
individual pigs and oral fluid samples from each pen post-vaccination and post-challenge 
were analyzed for the presence of anti-PRRSV antibody using the PRRSV X3 ELISA 
(IDEXX, Westbrook, ME). 
 
Immunohistochemistry Staining 
 Immunohistochemistry (IHC) staining for the detection of PRRSV-specific 
antigen was performed on lung sections at the ISU-VDL as previously described.
17
 
Sections were scored for magnitude of immunoreactive signals by a single veterinary 
pathologist blinded to the study, using the following scale: 0=normal, 1=minimal, 
2=mild, 3=moderate. Scores were averaged to obtain an overall treatment group mean for 
descriptive statistics. 
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Statistical Analysis 
A statistical analysis was performed between the vaccinated/challenged and non-
vaccinated/challenged groups. Descriptive summary statistics were performed for the 
non-vaccinated/non-challenged group. Percent lung lesions were transformed by the 
arcsine-square root transformation and were analyzed by a general linear mixed model 
approach. Microscopic lung lesions, virus levels in lung tissue, BALF, tonsil, oral fluids 
and serum and average daily gain were analyzed using the same statistical model. The 
SAS Proc Mixed procedure (SAS, Cary NC) included the fixed effect of treatment and 
the random effects of room, block-within-room and treatment-by-block-within-room. 
Treatment least squares mean (LS Mean) were calculated for each group. Pair-wise 
comparisons of LS Means between the two groups were performed by the two-sided 
Student’s t-test at the 5% level of significance. A p-value < 0.05 was considered 
significant. 
 
Results 
Pre- and Post-screening Microbiological Assays 
No extraneous viral or bacterial nucleic acids were detected in serum (PRRSV, 
PCV2) or nasal swabs (IAV, MHP) from pigs prior to the start of the experiment. All pigs 
were free of anti-PRRSV and -MHP antibodies as well as influenza A nucleoprotein 
antibody prior to the start of the study. Anti-PCV2 antibody was detected in 54/56 pigs 
prior to the start of the experiment. BALF collected from all pigs at necropsy (12 dpi) 
tested negative for PCV2, IAV, and MHP nucleic acid. 
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Pre-challenge PRRSV ELISA and RT-PCR 
Twenty-one of 23 and 23/23 pigs in the V/C group were PRRSV ELISA antibody 
positive at 14 and 28 dpv, respectively. Fostera™ PRRS vaccine virus was detected in 
serum by PCR in 87% (20/23) and 100% (23/23) of pigs at 14 and 28 dpv, respectively. 
All pigs in the NV/NC and NV/C groups were PRRSV PCR and PRRSV antibody 
negative in serum during the pre-challenge phase of the study. 
 
Clinical Disease 
Pigs in the NV/NC group did not exhibit clinical signs of respiratory disease for 
the duration of the study. Clinical signs of respiratory disease were not observed in the 
NV/C or V/C groups from 0 to 28 dpv. Approximately 75% of pigs in the NV/C group 
became depressed, lethargic, and moderately anorexic at 5 dpi; peak severity of clinical 
disease was apparent at 10 dpi characterized by moderate dyspnea, lethargy and marked 
anorexia. Approximately 50% of the V/C pigs displayed mild lethargy and anorexia from 
5-12 dpi. Significant differences were not observed between the V/C and NV/C group 
mean body temperatures at any time point during the study (data not shown). 
 
Lung Pathology 
Macroscopic lesions in the NV/C and V/C group were characterized by moderate 
to marked enlargement of tracheobronchiolar lymph nodes and variable percentage of 
lung surface affected by mottled-tan pneumonia lesions consistent with PRRSV infection. 
Mean percent pneumonia was decreased in the V/C group (mean 12.63%; range 0-50%) 
compared to the NV/C group (mean 17.21%; range 2-58%); however, the difference in 
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gross lung lesions was not statistically significant (Table 3). The NV/NC group mean was 
1.5% (range 0-12%).  
Microscopic lung lesions consisted of multifocal to diffuse, mild to severe 
lymphohistiocytic interstitial pneumonia. Microscopic interstitial pneumonia scores were 
minimally decreased in the V/C group (mean 2.47; range 1.0-4.6) compared to the NV/C 
group (mean 2.57; range 0.8-4.6); however, the difference in microscopic lung lesions 
was not statistically significant. The NV/NC mean microscopic lung lesion score was 
0.78 (range 0.4-1.0). 
 
Post-challenge PRRSV Quantitative RT-PCR 
PRRSV virus was not detected by RT-PCR in serum or oral fluid from the 
NV/NC group at any time during the study. PRRS challenge virus was detected in serum 
from all pigs in the NV/C and V/C groups at 3, 7 and 12 dpi. Mean PRRSV log10 
genomic copies/ml of serum from V/C pigs was significantly lower compared to NV/C 
pigs at 3, 7, and 12 dpi (Table 4).  
All pen-based oral fluid samples from NV/C and V/C groups were positive for 
PRRS challenge virus at 3, 7, and 12 dpi. Mean PRRSV log10 genomic copies/ml of oral 
fluid from V/C pigs was decreased compared to oral fluid from NV/C pigs at 3 and 7 dpi; 
however, the difference between groups was not statistically significant. Mean PRRSV 
log10 genomic copies/ml of oral fluid was significantly lower in V/C pigs at 12 dpi 
compared to NV/C pigs (Table 4). 
PRRSV was not detected in tissues collected from the NV/NC group at necropsy. 
Mean log10 genomic copies/ml of the challenge virus in BALF was significantly lower in 
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the V/C pigs compared to the NV/C group (Table 3). Mean log10 genomic copies/ml of 
the challenge virus in lung homogenate was lower in V/C pigs compared to NV/C pigs 
but not statistically significant. In contrast, the V/C group had higher amounts of 
challenge virus in tonsil homogenate compared to the NV/C group; however, this 
difference was not significant.  
 
Post-Challenge PRRSV ELISA Antibody 
All pigs in the NV/NC group were PRRSV antibody negative via serum and oral 
fluids throughout the challenge period. All pigs in the V/C group were positive for 
PRRSV ELISA antibody in serum at 3 and 7 dpi with mean S/P ratios of 1.13 and 1.28, 
respectively (Figure 1). At 12 dpi, 21/23 pigs in the V/C group were positive for serum 
antibody to PRRSV, with a mean S/P ratio of 1.23. PRRSV ELISA antibody was also 
detected in pen-based oral fluid samples at 3, 7 and 12 dpi in the V/C group, with mean 
S/P ratios of 2.48, 4.01, and 4.41, respectively (data not shown). Post-challenge, 0/24, 
21/24, and 24/24 pigs in the NV/C group were PRRSV ELISA antibody positive via 
serum at 3, 7, and 12 dpi, respectively. The NV/C group was PRRSV ELISA antibody 
negative via oral fluid at 3 dpi, and PRRSV ELISA antibody positive at 7 and 12 dpi, 
with mean S/P ratios of 0.97 and 4.21, respectively (data not shown).  
 
Production Parameters 
A statistical difference was not observed in mean average daily gain (ADG) 
between NV/C and V/C pigs from vaccination until challenge. Post-challenge mean ADG 
 80   
 
    
was significantly higher in the V/C group (0.44 kg/day) compared to the NV/C group 
(0.32 kg/day) (Table 5). The post-challenge ADG in the NV/NC group was 0.83 kg/day.  
 
Immunohistochemistry 
  Lung sections from all non-challenged control pigs were negative for PRRSV-
antigen via IHC scoring. Mean lung section IHC scores for vaccinated and challenged 
pigs were 0.96 (range 0-3), while non-vaccinated and challenged pigs had a mean IHC 
score of 0.75 (range 0-3).  
 
Discussion 
 Since its emergence in the late 1980’s, PRRSV has become the most 
economically important disease of the swine industry. Vaccination against the virus may 
be utilized in various control programs to prevent the introduction of a new strain or aid 
in the production of PRRSV negative pigs at weaning. MLV vaccines have demonstrated 
more effective control compared to inactivated vaccines when challenged with a 
homologous PRRSV; however, MLV vaccines have only demonstrated the ability to 
induce partial protective immunity against heterologous challenge.
11
 PRRSV vaccine 
challenge studies have typically used prototype isolates as the cell-culture challenge 
virus. Due to the large amount of genetic and antigenic diversity in PRRSV isolates, 
historical prototype viruses, such as VR2332 and MN-184, may not represent the 
genotypic or phenotypic characteristics of current strains circulating in swine that 
vaccine-induced immunity must protect against.  
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The objective of the current study was to evaluate the efficacy of a commercial 
MLV vaccine, Fostera™ PRRS, against a heterologous lineage 1 PRRSV recently 
isolated from nursery pigs in Iowa in 2014. Lineage 1 viruses are currently the most 
common PRRSV circulating in the US swine population demonstrating the greatest 
sequence divergence among field viruses.
18,19
 Several recent lineage 1 virus isolates were 
identified from case submissions at the ISU VDL. Isolate 14-4099 was selected as the 
challenge virus after an initial pilot study confirmed its virulence in swine. Results of the 
current study suggest Fostera™ PRRS vaccine administered four weeks prior to 
challenge elicited partial cross-protection against a heterologous lineage 1 challenge virus 
that shares only 84.4% ORF5 nucleotide homology. Vaccinated pigs had significantly 
lower levels of viremia at all sampling points, and vaccinated pigs had lower levels of 
virus in oral fluids and BALF at 12 dpi. In spite of these differences in virus levels 
between vaccinated and non-vaccinated pigs, gross and microscopic lung lesions (while 
trending lower in vaccinated pigs) did not demonstrate significant differences between 
the challenge groups. It is unknown why significant differences in lung lesions were 
lacking between challenge groups, in spite of the differences in viremia. Previous studies 
suggest increasing genetic diversity between challenge and vaccine viruses may affect 
vaccine efficacy demonstrated by similar severity of lung lesions regardless of the 
vaccine administered.
12
 PRRSV has a tropism for pulmonary alveolar macrophages 
(PAMs), which are the target of viral replication in swine.
20
 Levels of challenge virus in 
BALF in the current study suggest viral replication was decreasing at 12 dpi although it is 
possible sufficient time was lacking for differences in viral clearance from lung and tonsil 
to be detected as suggested by the similar magnitude of IHC signals observed in lung 
 82   
 
    
sections from both challenge groups, regardless of vaccination. Severity of lung lesions 
may also be influenced by the virulence of the challenge virus, dose, routes of 
administration and differences in host immune response. Collectively, pigs administered 
Fostera™ PRRSV demonstrated lower levels of virus in serum at all sample collections 
suggesting partial efficacy imparted by the vaccine.     
The impact of co-mingling pigs in the same room may have also affected the 
magnitude of lung lesions observed in challenged pigs regardless of vaccination status. 
Research has shown that vaccinated boars shed lower amounts of virus in semen than 
non-vaccinated boars.
21
 Studies in growing pigs have shown that therapeutic vaccination 
can decrease the amount of virus shed in herds endemically infected with homologous
8
 or 
heterologous PRRSV strains.
22
 In addition, experimental studies have reported the ability 
of infected pigs to transmit PRRSV to sentinel pigs via aerosols over short distances.
23
 
These studies suggest that co-mingling pigs could effectively expose vaccinated pigs to a 
greater dose of PRRSV throughout the post-challenge period (due to viral shedding from 
non-vaccinated roommates) compared to being exposed to pigs administered a similar 
treatment. While it is unclear what affect this may have on the dynamics of PRRSV 
infection, an artificial increase in virus levels detected in lung and elevated lung lesions 
are plausible outcomes. 
In this study, each pig was given a standard dose of challenge virus. Oral fluids 
from vaccinated pigs contained lower amounts of virus than oral fluids from non-
vaccinated pigs at 12 dpi, indicating that vaccination had resulted in lower quantities of 
virus being shed. Nose-to-nose contact would allow direct exposure to oral fluids, while 
aerosol transmission within each room also would be expected. Higher levels of 
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challenge virus shed from non-vaccinated pigs to vaccinated pigs may have contributed 
to the lack of difference in lung lesions or level of viral clearance in lung tissue; however, 
significantly lower levels of viremia and decreased PRRSV challenge virus in BALF 
from the vaccinated pigs would appear to contradict this theory. While the differences in 
serum and BALF virus quantities were still significant, the differences may have been 
falsely reduced from expected levels if pigs had not been co-mingled in the same room. 
Collectively, it could be argued that the co-mingling of vaccinated and non-vaccinated 
pigs post-challenge may affect the results of several commonly assessed parameters of 
immune protection. 
Much of the losses attributed to PRRSV infection in growing pigs are due to 
increased mortality, decreased ADG, and decreased feed efficiency. In this study, a 
significant difference in average daily gain between vaccinated and non-vaccinated pigs 
was apparent after only 12 days post challenge with a virulent PRRSV. This suggests that 
vaccination with Fostera™ PRRS confers significant production benefits in the face of 
heterologous challenge. Considering clinical severity was at its peak at the time of 
necropsy in NV/C pigs, extending the post-challenge period may have further increased 
the difference in ADG between V/C and NV/C groups. In addition, vaccination did not 
depress ADG in the pre-challenge period, suggesting immunity was elicited without a 
concurrent decrease in production. The improved weight gain may be partially explained 
by the reduced viremia and reduced virus levels in BALF.  
In summary, vaccination of nursery pigs with Fostera™ PRRS resulted in partial 
cross-protection when challenged with a contemporary, heterologous lineage 1 PRRSV. 
Vaccinated pigs showed decreased viremia and increased ADG compared to non-
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vaccinated pigs; however, vaccination did not significantly decrease gross or microscopic 
lung lesions. Further investigation into cross-protection elicited by MLV vaccines is 
needed, along with research into the differences in cross-protection conferred by various 
commercial MLV vaccines. The results of this study show that the impact of PRRSV on 
growing pigs can be substantially mitigated through the use of MLV vaccines. In order to 
make substantial progress regarding PRRS control, future vaccine development should 
focus on the stimulation of broad heterologous cross-protection.  
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Table 1. Experimental design. 
 
Days post  
vaccination: dpv 
 
Days post inoculation: dpi 
Group N Blocks Age Vaccine Age Challenge 0 7 14 21 
 
0 3 7 12 
NV/NC 9 5 
4 
wks 
Non-
vaccinated 
8 
wks 
Non-
challenged 
S 
NS
OF 
OF 
S 
OF 
OF 
 
S 
OF 
S 
OF 
S 
OF 
S, OF 
Necropsy 
NV/C 24 12 
4 
wks 
Non-
vaccinated 
8 
wks 
ISU-14-4099 
S 
NS
OF 
OF 
S 
OF 
OF 
 
S 
OF 
S 
OF 
S 
OF 
S, OF 
Necropsy 
V/C 23 12 
4 
wks 
Fostera™ 
PRRSV 
8 
wks 
ISU-14-4099 
S 
NS
OF 
OF 
S 
OF 
OF 
 
S 
OF 
S 
OF 
S 
OF 
S, OF 
Necropsy 
NV/NC: non-vaccinated/non-challenged; NV/C: non-vaccinated/challenged; V/C: vaccinated/ challenged; S: serum; NS: nasal swab;  
OF: oral fluid; BALF: bronchoalveolar lavage fluid 
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Table 2. Sequences of the forward and reverse primers and individual probe for 14-4099 challenge PRRS virus used in the real 
time RT-PCR for absolute quantification of PRRSV genomic copies. 
Name Sequence 
PRRSV (forward primer) 5’-ATATCTCCACGGGCGGTATG -3’ 
PRRSV (reverse primer) 5’-TTGTAAGCCTGATGGCAAAGC-3’ 
14-4099 PRRSV 5’-/56-FAM/CTGTCTGCG/ZEN/CTCTTGCCGCG/3IABkFQ/-3’ 
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Table 3. Mean macroscopic pneumonia, microscopic lung lesion scores and quantitative RT-PCR values in lung, BALF and tonsil 
collected from NV/NC, NV/C and V/C pigs at 12 dpi ± standard error of the mean. Different letters within a column represent a statistical 
difference at P < 0.05. 
Group 
Lung Lesions  Quantitative PCR (Mean log 10 genomic copies/ml±SE) 
Macroscopic percent 
pneumonia 
(Mean±SE) 
Microscopic lung 
scores 
(Mean±SE) 
 
Lung BALF Tonsil 
NV/NC  1.5 ± 0.7         0.78 ± 0.08  0.00 ± 0.00 0.00 ± 0.00         0.00 ± 0.00 
NV/C 17.2  ± 3.2
a
 2.57 ± 0.26
a
  6.21  ± 0.19
a
  6.19 ± 0.21
a
 6.71 ± 0.11
a
 
V/C 12.7 ± 2.1
a
 2.47 ± 0.26
a
    6.04 ± 0.19
 a
  5.44 ± 0.21
b
 6.87 ± 0.11
a
 
NV/NC, non-vaccinated-non-challenged; NV/C, Non-vaccinated-challenged; V/C, vaccinated-challenged 
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Table 4. Mean PRRSV 14-4099 log10 genomic copies/ml ± standard error of the mean for serum and pen-based oral fluid samples from 
NV/NC, NV/C and V/C pigs collected at 3, 7 and 12 days post-inoculation (dpi). Different letters within a column are statistically 
different at P < 0.05. 
 Serum (Mean log 10 genomic copies/ml±SE)  Oral Fluid (Mean log 10 genomic copies/ml±SE) 
Group 3 dpi 7 dpi 12 dpi  3 dpi 7 dpi 12 dpi 
NV/NC 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00  0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
NV/C 6.92 ± 0.11
a
 7.07 ± 0.14
a
 5.38 ± 0.18
a
  4.83 ± 0.14
a
 5.12 ± 0.13
a
 4.36 ± 0.15
a
 
V/C 6.54 ± 0.11
b
 5.78 ± 0.14
b
 4.18 ± 0.19
b
  4.76 ± 0.14
a
 4.86 ± 0.13
a
 3.53 ± 0.15
b
 
NV/NC, non-vaccinated-non-challenged; NV/C, Non-vaccinated-challenged; V/C, vaccinated-challenged 
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Table 5. Average daily gain reported in kilograms during the post-vaccination and post-challenge 
phase of the study in NV/NC, NV/C and V/C groups ± standard error of the mean. Different 
letters within a column are statistically different at P< 0.05. 
  Average Daily Gain in Kilograms 
Group  Post-Vaccination 
(-10 to 26dpv)  
Post-Challenge 
(26dpv to 12dpi) 
NV/NC  0.441 ± 0.028  0.827 ± 0.026 
NV/C  0.405 ± 0.014
a  0.323 ± 0.027a 
V/C  0.405 ± 0.014a  0.441 ± 0.032b 
NV/NC, non-vaccinated-non-challenged; NV/C, Non-vaccinated-challenged; V/C, vaccinated-
challenged 
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Figure 1. Mean anti-PRRSV ELISA antibody S/P ratios in serum from NV/NC, NV/C and V/C 
pigs at 0, 14 and 28 days post vaccination (dpv) and 3, 7 and 12 days post inoculation (dpi). Error 
bars represent standard error of the mean. 
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Figure 2. Macroscopic and microscopic lung lesions and immunohistochemistry staining of lung 
observed at necropsy in (A) NV/NC, (B) NV/C and (B) V/C pigs challenged with placebo or 14-
4099 PRRSV. 
 
 
 
 
 
 
 
 
 
A 
C 
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CHAPTER 5: CONCLUSION 
 Reproductive failure, increased mortality, and reduced feed efficiency due to 
porcine reproductive and respiratory syndrome virus (PRRSV) combine to make it the 
mostly costly pathogen in modern swine production. Prevention and control of PRRSV is 
difficult due to the vast genetic diversity present within currently circulating virus strains. 
Protective immunity stimulated by natural infection or vaccination rarely results in 
complete protection from infection; however, vaccination with modified live virus 
(MLV) vaccines has been shown to result in partial protection, defined by an 
improvement in weight gain, less severe lung lesions, and/or reduced viremia. 
 The advancements made in vaccine development may play a crucial role in 
reducing the cost of disease, and someday may potentially result in PRRSV eradication. 
New vaccines must prove to be more effective than current commercially available 
vaccines, especially against relevant and contemporary field viruses. Most vaccine 
challenge studies have used historic PRRSV isolates in order to allow some level of 
comparison between results; however, historic isolates may be genetically and 
phenotypically different from current field strains and virulence among strains even 
within a PRRSV lineage may vary. A challenge model that uses currently circulating, 
virulent PRRSV isolates would provide a much more accurate depiction of how a vaccine 
could be expected to perform in current swine production settings.  
 With nine different lineages and thousands of available PRRSV isolates, the 
options for selecting a suitable challenge virus are nearly endless. One goal of the current 
research was to provide swine veterinarians and producers with information regarding a 
recently approved vaccine, Fostera™ PRRS. To ensure the results were relevant, the 
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following criteria for virus selection were as follows: 1) the challenge virus must belong 
to highly populated PRRSV lineage; 2) the challenge virus must be sufficiently 
heterologous to adequately evaluate cross-protection; and 3) the challenge virus must 
represent current circulating virus strains. Four of the nine lineage classifications have 
more than 1,000 different PRRSV.  Lineage 1 and lineage 9 are the two largest PRRSV 
lineages; viruses within these lineages also display the most intralineage genetic diversity 
at ORF5 of any of the large lineages.  
 In both studies presented in this thesis, the challenge PRRSV were chosen from a 
group of recently isolated field isolates. Small pilot studies using three pigs in each 
challenge group were used to examine the virulence of each virus and to ensure the 
challenge model would result in gross lung lesions that were easy to observe. In addition 
to proving the virulence of the challenge virus, several different parameters were 
investigated, including microscopic lung lesions, average daily gain, and the amount of 
virus detected in various fluids or tissues (serum, oral fluids, bronchoalveolar lavage 
fluid, lung, and tonsil), to use as a measure of the degree of vaccine protection. 
 The results of the two studies presented here share several similarities. Average 
daily gain of vaccinated pigs during the challenge period was greater than that of non-
vaccinated pigs in both studies, suggesting significant improvement in clinical disease 
that may be correlated with increased feed intake and improved feed efficiency although 
these parameters were not specifically measured during either experiment. Non-
challenged controls had better average daily gain than non-vaccinated challenged pigs, 
which serves as a testament to the virulence of the challenge viruses; however, vaccinated 
pigs gained less weight than non-challenged controls as well, suggesting a level of partial 
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protection but with considerable room for improvement. Viremia was improved at 3, 7 
and 12 days post inoculation and fewer viral genomic copies were also present in BALF 
at necropsy in both studies. Interestingly, both experiments detected higher levels of 
PRRSV in the tonsil tissue of vaccinated pigs. This unexpected result may be due to 
several factors, including processing difficulty due to the tough fibrous nature of the 
tissue, or perhaps priming the immune system via vaccination leads to enhanced viral 
uptake and replication in lymphoid tissue. PRRSV persists in lymphoid tissues of 
infected pigs even after clearance of the virus from the blood. However, it remains 
unknown why the vaccinated pigs demonstrated larger quantities of challenge virus in the 
tonsil compared to non-vaccinated and challenged pigs in the current studies. 
 While there were some similarities between the challenge experiments described 
in Chapter 2 and 3, there were also many differences between studies. The lineage 9 
study demonstrated nearly a two log reduction in serum virus quantities in the vaccinated 
pigs at 7 and 12 dpi and no significant difference prior to that time. Vaccinated pigs also 
demonstrated lower levels of virus in lung tissue, along with significantly decreased gross 
and microscopic lung lesions. Challenge with a lineage 1 virus did not result in a decrease 
in lung lesions or virus load in the lung tissue, but did show a decrease in viremia at each 
measured timepoint (3, 7 and 12 dpi). The reasons for the discrepancies between studies 
are unknown; however, variation in study design (20 pigs per pen in the lineage 9 study 
and 2 pigs per pen with 12 replicates in the lineage 1 study), pig housing, and challenge 
virus along with differences in the individual pig’s susceptibility and response to PRRSV 
infection may all play a role. 
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 Along with random differences in the groups of pigs used in each study (although 
sourced from the same farm), two major differences are likely to have contributed to the 
variable results. First, the lineage 1 study used a challenge virus that was considerably 
more genetically diverse than the lineage 9 challenge virus regarding their homology to 
the vaccine PRRSV strain. Vaccines have been shown to be completely protective against 
homologous viruses used in challenge studies, so it stands to reason that a vaccine may 
offer a higher level of protection against a less genetically or antigenically diverse strain 
compared to a more diverse strain. The lineage 9 challenge virus shares 92.5% ORF5 
homology with the vaccine virus, while the lineage 1 challenge virus is only 84.4% 
homologous at ORF5. This difference may account for the relatively higher degree of 
protection seen in the lineage 9 challenge study based on the reduction in lung lesions 
and reduced virus levels in lung tissue. 
 The second major difference involves the study design. The lineage 9 challenge 
study housed vaccinated and non-vaccinated pigs in separate rooms for the duration of 
the study (both pre-challenge and post-challenge periods). Pigs in each room were also 
kept in one large pen. The lineage 1 challenge study housed vaccinated pigs and non-
vaccinated pigs in separate rooms for the pre-challenge period only, and pigs were 
divided into pens of two in each room. On the day of challenge, one-half of the pigs were 
moved into the opposite treatment room, in an attempt to eliminate potential room bias.  
 The design of the lineage 9 study eliminated any exposure to challenge virus 
between pigs from different treatment (vaccination) groups, and more accurately reflects 
what could be expected to occur in modern pig production when an entire group of pigs 
are administered the same vaccine at the same time. It allowed us to compare the 
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differences between an entire room of vaccinated pigs and an entire room of non-
vaccinated pigs, to see if vaccination of a single room had any effect on post-challenge 
production. Each pig was individually vaccinated and challenged; during the post-
challenge period, any additional virus contacted by the pig was due to the dynamics of 
infection and subsequent shedding of pen-mates within a treatment group, either with or 
without the potential benefit of vaccination. Room bias may have been present in the 
lineage 9 study, but in a climate-controlled infectious disease research facility with 
identical room dimensions, I believe the consequences to be insignificant and of 
irrelevant impact. 
 The design of the lineage 1 study removed room bias by co-mingling an equal 
number of pigs from each treatment group in each room, but in separate pens. Each pig 
was vaccinated and challenged individually; however, pigs in different treatment groups 
were allowed nose-to-nose contact. Therefore, at challenge, vaccinated pigs had direct 
contact with non-vaccinated pigs exposing vaccinated pigs to higher levels of PRRSV 
shedding into the environment compared to what would have been expected in a room 
containing pigs with the same treatment (vaccination vs. no vaccination). Conversely, 
with half of the pigs in each room vaccinated, non-vaccinated pigs came into contact with 
lower levels of virus. The study design effectively changed the exposure dose of each pig 
although it is unknown how that may have affected the effectiveness of vaccine-induced 
immunity in regards to parameters such as lungs lesions and weight gain.  
 The results of the studies presented here suggest vaccination provided partial 
protection as measured by a reduction in virus quantities in serum and increased weight 
gain. Interestingly, this protection was seen in the absence of neutralizing antibodies. 
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Serum from Fostera™ PRRS-vaccinated sows was tested for the presence of neutralizing 
antibodies toward 12-39404 (the challenge virus used in the lineage 9 challenge study) 
and showed a complete lack of neutralization. Antibody neutralization of the lineage 1 
challenge strain, 14-4099, was not directly tested; however, due to the large amount of 
genetic diversity between this strain and the vaccine strain, neutralizing antibodies to a 
strain with that degree of diversity would not be expected. These results suggest that 
while neutralizing antibodies may be helpful (or even necessary) in preventing viremia, 
they are not needed to provide partial protection as measured by a reduction in viremia 
and improved production. 
 With the absence of complete protection from infection, the improvement in 
average daily gain observed in both studies is the most impressive aspect of vaccine-
induced partial protection. The lineage 1 study ADG was particularly interesting, since no 
difference in gross or microscopic lung lesions were detected by a subjective analysis but 
based on expertise and published parameters. In a production setting with large numbers 
of animals, small increases in efficiency can have a large impact on the economics of 
disease. In addition to improved post challenge ADG, post vaccination average daily gain 
was not significantly different in either study. In other words, there are no negative 
effects on production due to vaccination with Fostera™ PRRS under the conditions of the 
experiments. In production systems with a high-risk of PRRSV exposure, producers can 
receive the benefit of partial protection without sacrificing production due to vaccination.  
 In order to eventually have any chance of eradicating PRRSV, science likely must 
develop a vaccine that confers complete (or near-complete) protection against 
heterologous infection. The rate of genetic change in field isolates will be a limiting 
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factor in the future effectiveness of current vaccines.  More research is needed into highly 
conserved epitopes and antibodies to those epitopes that may provide broad cross-
protection against current and future virus strains. There is a possibility that such epitopes 
may not exist, and vaccine development may need to explore new alternatives, such as 
nanoparticle or recombinant based vaccines. 
 In the meantime, more research is needed to determine the cross-protective 
efficacy of other commercial vaccines against challenge with PRRSV strains that are 
currently circulating in the world’s swine population. Improving our knowledge of 
vaccine-induced immunity and its effect on various viruses can aid in the selection and 
directed use of the most appropriate vaccine for each production setting. Genetic 
sequencing of regional PRRSV strains may allow for widespread use of targeted 
vaccination programs in an effort to reduce the impact of PRRSV. Sequencing can also 
be useful in tracking the spread of the virus and identifying emerging routes of viral 
dissemination. Research into the various aspects of PRRSV has uncovered much of the 
mystery that initially surrounded the disease, but there is still much to learn. 
